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6ABSTRACT
Nutrition affects bone health throughout life. To optimize peak bone mass development and
maintenance, it is important to pay attention to the dietary factors that enhance and impair
bone metabolism. In this study, the in vivo effects of inorganic dietary phosphate and the in
vitro effects of bioactive tripeptides, IPP, VPP and LKP were investigated.
Dietary phosphate intake is increased through the use of convenience foods and soft drinks
rich in phosphate-containing food additives. Our results show that increased dietary phosphate
intake hinders mineral deposition in cortical bone and diminishes bone mineral density (BMD)
in the aged skeleton in a rodent model (Study I). Phosphate elevates parathyroid hormone
(PTH) concentration and conserves trabecular bone, as mineral loss was lower in the lumbar
spine with a phosphate-rich diet. In the growing skeleton (Study II), increased phosphate
intake was observed to reduce bone material and structural properties, leading to diminished
bone strength. Studies I and II revealed that a low Ca:P ratio has negative effects on the
mature and growing rat skeleton even when calcium intake is sufficient.
High dietary protein intake is beneficial for bone health. Protein is essential for bone turnover
and matrix formation. In addition, hydrolysis of proteins in the gastrointestinal tract produces
short peptides that possess a biological function beyond that of being tissue building blocks.
The effects of three bioactive tripeptides, IPP, VPP and LKP, were assessed in short- and
long-term in vitro experiments. Short-term treatment (24 h) with tripeptide IPP, VPP or LKP
influenced osteoblast gene expression (Study III). IPP in particular, regulates genes associated
with cell differentiation, cell growth and cell signal transduction. The upregulation of these
genes indicates that IPP enhances osteoblast proliferation and differentiation. IPP was
confirmed to increase UMR-106 and hMSC proliferation, but not the proliferation of mature
osteoblasts. Long-term treatment with IPP enhanced osteoblast gene expression in favour of
bone formation and increased mineralization (Study IV), but did not influence osteoblast
differentiation in vitro. The in vivo effects of IPP on osteoblast differentiation might differ
since eating frequency drives food consumption, and protein degradation products, such as
bioactive peptides, are available periodically, not continuously as in this study.
To sum up, Studies I and II raise concern about the appropriate amount of dietary phosphate
to support bone health as excess is harmful. Studies III and IV in turn, support findings of the
beneficial effects of dietary protein on bone and provide a mechanistic explanation since cell
proliferation and osteoblast function were improved by treatment with bioactive tripeptide
IPP.
7ABBREVIATIONS
ACE, angiotensin-I-converting enzyme
ALP, alkaline phosphatase
Apaf, apoptotic protease-activating factor
BMD, bone mineral density
BMP, bone morphogenetic protein
BMU, basic multicellular units
cAMP, cyclic adenosinmonophosphate
CaR, calcium-sensing receptor
Cbfa1/Runx2, core binding factor alpha 1/runt-related gene 2
CREB-5, cAMP response element binding protein 5
Dkk, Dickkopf homologue
ECM, extracellular matrix
FADD, Fas-associated death domain
FGF, fibroblast growth factor
Fz, frizzled receptor
GIP, gastric inhibitory polypeptide
GLP, glucagon-like peptide
Hh, hedgehog
hPepT, human di/tri-peptide transporter
IGF, insulin-like growth factor
Ihh, Indian hedgehog
IPP, Ile-Pro-Pro
LKP, Leu-Lys-Pro
LRP low-density lipoprotein receptor-related protein
M-CSF, macrophage colony-stimulating factor
NF-?B, nuclear factor kappa B
Npt, Na/Pi co-transporter
OCN, osteocalcin
OPG, osteoprotegerin
Osx, osterix
OVX, ovarectomy
PBM, peak bone mass
Pi, inorganic phosphate
PKA, protein kinase A
PTH, parathyroid hormone
PTHrP, parathyroid hormone-related peptide
RANKL, receptor activator of nuclear factor kappa B ligand
RGD, Arg-Gly-Asp
TGF, transforming growth factor
VPP, Val-Pro-Pro
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91 INTRODUCTION
The World Osteoporosis Day on the 20th of October 2006 was themed ‘Bone appetite’  to
focus on the role of nutrition in building bones. Osteoporosis is a disease characterized by
brittle and porous bones that are prone to fracture. The disease affects about 75 million people
in Europe, USA and Japan. The International Osteoporosis Foundation estimated the total cost
of osteoporotic fractures to be €  31.7 billion in Europe in 2002. As the population ages, the
number of individuals with osteoporosis will increase and the cost incurred by society will, in
turn, rise.
Prevention is the most cost-effective means of tackling the osteoporosis issue. Bone mass
attained early in life may be the most important determinant of lifelong bone health (NIH
consensus conference 2001). Genetic factors play a predominant role in peak bone mass
(PBM) development, but physiological, environmental and modifiable lifestyle factors can
also have a significant role. A balanced diet, adequate energy and nutrient intake lay the
foundation for all tissue development, including bone. Calcium is the most important nutrient
for attaining PBM and for preventing bone loss. Several vitamins, such as vitamin D (calcium
absorption), and vitamins A, K, and E (bone matrix synthesis), are associated with bone
health. Other nutritional aspects, such as eating patterns (consumption of fruits and vegetables
boosts bone health) and eating frequencies (frequent meals enhance bone health, likely
through gastrointestinal hormone secretion), also affect bone health. One goal for nutritional
research in the bone field is to establish the optimal diet to enable maximal PBM development
and to maintain the bone mass achieved. Nutrients important for bone should be
recommended, but bone-impairing nutrients must also be elucidated.
This thesis is composed of in vivo (Studies I and II) and in vitro (Studies III and IV) studies
exploring the effects of inorganic dietary phosphate and bioactive peptides on bone
metabolism. The work contributes to a better understanding of the mechanisms of action of
phosphate and bioactive peptides on bone at the tissue and cellular level.
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2 REVIEW OF THE LITERATURE
2.1 Structure and function of bone
Bone tissue consists of an organic matrix, minerals and bone cells. A major organic
component is type I collagen, but other proteins, such as osteocalcin, osteonectin and
osteopontin, are also present. The main mineral in bone is hydroxyapatite (Ca10(PO4)6(OH)2),
found in conjunction with carbonate, citrate, magnesium, sodium, fluoride and strontium ions.
Bone cells comprise a population of cells of heterogeneous origin and restricted function with
respect to matrix formation, mineralization and resorption. The local mesenchymal origin of
bone-forming osteoblast cells differs from that of extraskeletal, hemopoietic bone-resorbing
osteoclast relatives. However, the functions of these two diverse populations are strongly
related and interdependent.
The bone formed through the ossification process can be divided into compact cortical bone
and spongiosa trabecular bone. Trabecular bone forms 20% of bone mass, but its high
remodelling rate renders its metabolic activity equal to that of cortical bone (Eriksen et al.
1994). Bone remodelling is a surface phenomena and because trabecular bone has more
surface area than cortical bone, also the remodelling rate is higher (Arnett 2003). Furthermore,
trabecular and cortical bone have different functions. Trabecular bone has more of a
"metabolic" function in quickly releasing mineral ions into blood and cortical bone has more
of a mechanical and protective function.
2.1.1 Osteoblasts
The osteoblast lineage consists of osteoblasts, osteocytes and bone-lining cells. Osteoblasts
are bone-forming cells that synthesize and secrete most of the proteins of the bone
extracellular matrix (ECM) and also express the genes necessary and sufficient to induce
mineralization. During bone formation some osteoblasts become entrapped in the mineralized
matrix and differentiate further into osteocytes. Approximately one in 12 osteoblasts undergo
this change (Noble 2003). Osteocytes are the most abundant cell type in bone, outnumbering
osteoblasts by a factor of ten (Manolagas 2000). They have a stellate morphology and they
form a dentritic network throughout the mineralized matrix. Osteocytes use this network to
communicate with each other and the cells on the bone surface. Osteocytes function as the
mechanosensors to start bone remodelling in order to adapt bone architecture to the
mechanical needs of the skeleton (Noble & Reeve 2000). Evidence also indicates that
osteocyte apoptosis attracts osteoclasts to damaged bone areas to initiate the remodelling
process (Noble et al. 1997). Intact osteocyte network inhibits osteoclast activity by secreted
signal molecules but if the network is damaged inhibition ceases and osteoclasts attach to the
bone to start resorption (Gu et al. 2005). Instead of differentiating into osteocytes, some
osteoblasts become bone-lining cells. These are flat, elongated cells on top of the
unmineralized collagen matrix. Evidence suggests that lining cells are capable of reverting
back to osteoblasts (Bellido et al. 2003), but they are also thought to be the target cells of
osteocyte signalling (Manolagas 2000, Noble & Reeve 2000). In response to osteocyte signals,
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lining cells are likely to be the ones prepairing the bone surface for osteoclast attachment
(Manolagas 2000).
Figure 1: Bone marrow-derived mesenchymal stem cells are capable of differentiating into
adipocytes, chondrocytes, osteoblasts, and myocytes. Osteoblast differentiation is potentiated
with factors such as PTHrP, BMP-2, FGF, IGF-I and –II. The first gene associated with
osteoblast differentiation is Ihh, followed by Cbfa1/Runx2. Osteoblast progenitor cell
expresses collagen type I. Osterix (Osx) gene is expressed downstream of Cbfa1/Runx2 in
pre-osteoblasts. Osx promotes osteonectin expression. In mature osteoblasts the expression of
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non-collagenous proteins, such as osteocalcin is further increased. After completing bone-
forming function osteoblast can turn into bone lining cell or osteocyte, but the majority of
cells die of apoptosis.
2.1.1.1 Osteoblast differentiation
The same pluripotent mesenchymal stem cells that differentiate into chondrocytes during
endochondral ossification are also capable of differentiating into myoblasts, adipocytes and
osteoblasts (Figure 1). The osteoblast differentiation process is regulated by hormones and
cytokines that activate osteoblast-specific signalling proteins and transcription factors.
There are at least two osteogenic pathways: hedgehog (Hh) and Wnt. The Hh signalling
pathway influences transcription of many genes (for review, see Hooper & Scott 2005). The
three Hh genes in mammals, sonic (Ssh), Indian (Ihh) and desert hedgehog (Dhh), are
expressed in different tissues and at different stages of development, and might vary in
biological activity. During endochondral ossification the pre-chondrocytes in the cartilage-
forming model express Ihh, which plays a role in coordinating the growth and differentiation
of chondrocytes (Mak et al. 2006, Rodda & McMahon 2006). In addition, Ihh initiates the
osteogenic programme in osteoblast progenitors and is required for osteoblast development in
vivo (Long et al. 2004). Hh signalling acts at the early stages of osteoblast differentiation,
activating the expression of Cbfa1/Runx2, collagen 1 and alkaline phosphatase (Hu et al.
2004).
Core binding factor alpha 1 (Cbfa1), also called runt-related gene 2 (Runx2), is the most
extensively studied osteogenic transcription factor. Cbfa1/Runx2 is necessary for osteogenesis.
Cbfa1/Runx2 activates osteocalcin, an osteoblast-specific gene expressed by fully
differentiated osteoblasts (Ducy 2000). Cbfa1/Runx2-deficient mice lack bone formation
because of a maturation arrest of osteoblasts (Komori et al.1997). However, Cbfa1/Runx2
alone is not sufficient for osteogenesis. Thus, besides Cbfa1/Runx2, other transcription factors
are needed to activate the genetic pathways controlling osteoblast differentiation.
In addition to initiating osteoblastogenesis, Hh induces the expression of Wnt ligands. The
Wnt proteins are a family of 19 secreted signalling molecules (Kuhl 2004). Wnts are
important in osteoblast differentiation. The Wnt/?-catenin canonical pathway is activated
when Wnt binds to the frizzled receptor (Fz) and the low-density lipoprotein receptor-related
protein 5 and 6 (LRP5/6) co-receptor located on the cell membrane (Figure 2). The signals
generated stabilize ?-catenin and the accumulated protein is then translocated to the nucleus,
where it functions as a transcriptional co-activator (Krishnan et al. 2006).
The Wnt/?-catenin pathway regulates bone development through different mechanisms during
different stages of life (Krishnan et al. 2006, Rodda & McMahon 2006). In the early stages of
osteoblastogenesis, the Wnt/?-catenin pathway stimulates Cbfa1/Runx2 expression (Gaur et al.
2005), and in the later stages it downregulates RANKL expression (Spencer et al. 2006). In
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addition to stimulating osteoblastogenesis and reducing osteoclastogenesis, the Wnt/?-catenin
pathway represses adipogenesis (Bennett et al. 2002, Arango et al. 2005) and protects against
apoptosis (Day et al. 2005, Krishnan et al. 2006). An interesting aspect of the Wnt/?-catenin
pathway is that mechanical stimulation enhances bone mass through LRP5 signalling and
causes ?-catenin to translocate to the nucleus (Robinson et al. 2006, Sawakami et al. 2006).
Furthermore, LRP5 appears to be a potent regulator of bone mass, size and strength
(Sawakami et al. 2006). Wnt signalling can be downregulated by Dickkopf homologue 1
(Dkk1). The inhibiton of Wnt signalling and the removal of ?-catenin prevents the maturation
of osteoblasts (Hu et al. 2004, Rodda & McMahon 2006). While canonical Wnt signalling
itself is not sufficient to promote osteoblast differentiation, it can synergize with bone
morphogenetic protein (BMP) signalling (Day et al. 2005).
Figure 2: The canonical Wnt signalling pathway. The left figure shows the degradation of β-
catenin through interaction with Axin, APC and glycogen synthase kinase-3 (GSK3).
Dickkopf homologue 1 (Dkk1) prevents Wnt from binding to the Frizzled receptor. Right
figure shows the binding of Wnt protein to the Frizzled/LRP5/6 co-receptor complex. The
activation of Dishevelled (Dsh) causes Axin to be recruited to the membrane and interact with
LRP5/6. The inactivation of GSK3 results in the stabilization and accumulation of β-catenin
in the cytoplasm and nucleus. In the nucleus, β-catenin interacts with T-cell factor/lymphoid
enhancer binding factor (TCF) and activates transcription of Wnt/β-catenin target genes
(Logan & Nusse 2004).
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BMPs are members of the transforming growth factor-? (TGF-?) superfamily, and their
fundamental function is to induce differentiation of mesenchymal cells into cells of the
osteoblastic lineage (Canalis et al. 2003). As a result, the pool of mature osteoblastic cells
increases (Canalis et al. 2003). The BMP family can be divided into several subgroups based
on BMP gene sequence identity. In osteoblasts, BMPs regulate growth, differentiation and
apoptosis. BMP-2, BMP-4 and BMP-7 upregulate Cbfa1/Runx2 expression, inducing
osteoblast differentiation (Yamaguchi et al. 2000, Phimphilai et al. 2006). BMP-6 induces
osteoblast differentiation and maturation (Ebisawa et al. 1999) and is involved in in vitro bone
nodule formation (Yamaguchi et al. 2000). In an ovarectomy (OVX) rodent model, BMP-6
increased bone volume, enhanced bone microarchitecture and restored bone quality (Simic et
al. 2006). BMP-5 is closely related to BMP-6, as they both belong to the same subgroup of
the BMP family tree. Hence, BMP-5 has similar osteoinductive properties (Wozney 2002).
BMP-5 plays a role in fracture healing, and one characteristic of BMP-5 null mice is impaired
fracture repair (Canalis et al. 2003).
BMPs and Wnts are important signals in osteoblast differentiation. Notch is a signaling
pathway opposingWnt/?-catenin signaling (Deregowski et al. 2005, Zamurovic et al. 2004).
Notch proteins are transmembrane receptors that play a critical role to control cell fates.  The
Notch signaling pathway is activated through direct cell–cell contact of the Notch receptor
with one of its ligands. Notch interaction with Wnt signaling decreases ?-catenin and prevents
the transcription of Wnt target genes (Deregowski et al. 2005). Notch ligand Jagged1 plays an
important role in MSC differentiation. In osteoblasts Jagged1 is regulated by PTH through the
activation of the AC/PKA pathway (Weber et al. 2006). Jagged1/Notch signaling modulates
osteoblastic differentiation but there is controversy wether it is impaired (Sciaudone et al.
2002) or enhanced (Tezuka et al. 2002).
During in vitro differentiation from an osteoprogenitor to a mature osteoblast, three distinct
phases can be distinguished that reflect the maturation stages of osteoblasts in vivo
(Dworetzky et al. 1990): proliferation, matrix maturation and mineralization. Different
markers have been associated with each of these phases. Markers are useful since in a cell
culture osteoblasts are nearly indistinguishable from fibroblasts and their only specific
morphological feature is the capability to form mineralized nodules (Ducy et al. 2000).  At the
proliferation phase, cell growth and cell cycle genes are actively expressed, as are type I
collagen genes (Owen et al. 1990). At the matrix maturation phase, alkaline phosphatase
(ALP) and osteopontin gene expression occurs. Osteoblast cell proliferation becomes limited
as the state of differentiation increases (Owen et al. 1990, Amédée et al. 1994, Qi et al. 2003).
Proliferation and differentiation are generally considered to be opposite and mutually
exclusive states in cell biology (Selz et al. 1989). At the onset of mineralization, the
expression of non-collagenous proteins (osteopontin and osteocalcin) is further increased, and
calcium and phosphate are deposited into the ECM (Owen et al.1990). OPG expression is also
increased at the onset of mineralization, remaining high in mature osteoblasts and resulting in
a lower RANKL/OPG ratio and suppression of osteoclast differentiation (Thomas et al. 2001).
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2.1.1.2 Bone formation
The adult skeleton contains 206 bones of different sizes and shapes according to function.
Bones give support to the body, protect delicate organs and act as a storage site for minerals
such as calcium. In human development, the origin of bone can be dated back to the first three
weeks of foetal life (see e.g. Olsen 2003). During this pre-embryonic period the cells giving
rise to all structures of the body differentiate into three germ layers. These layers are the
ectoderm (forming all nerve tissue and some epithelial tissue), the mesoderm (forming all
connective and muscle tissue and some epithelial tissue) and the endoderm (forming some
epithelial tissue).The ectoderm differentiates into the neuroectoderm and the epidermis. The
neuroectoderm forms the neural tube (eventually becoming the brain and spinal cord) and the
neural crest, while the epidermis covers the outside of the body. Facial bones and the cranium
derive from the neural crest. The paraxial mesoderm forms the base of the skull, parietal
bones and the axial elements of the ribs and vertebrae. The lateral plate of mesoderm forms
the sternum and long bones.
There are two types of bone formation: intramembranous and endochondral ossification (see
e.g. Olsen 2003, Lian et al. 2003). Both result in bone material with equal properties and
structure. Intramembranous ossification is a direct process where osteoblasts differentiate
from mesenchymal progenitors and bone is formed directly without a cartilaginous stage. This
type of bone formation takes place within the skull. Endochondral ossification begins with the
condensation of multipotent mesenchymal cells into structures that eventually become
skeletal elements. The first chondrocytes appear at around five weeks of embryo development.
In the developing cartilage, chondrocytes go through proliferation and differentiation.
Eventually, proliferative chondrocytes differentiate into hypertrophic chondrocytes secreting
factors such as Ihh and vascular endothelial growth factors, which are required for osteoblast
differentiation (Mak et al. 2006). The hypertrophic cartilaginous region is invaded by blood
vessels and osteoblastas already differentiated in the perichondrium. Osteoblasts then secrete
a calcified bony matrix. The ossification of cartilaginous model begins during the third month
of development. In addition to occuring during embryonic development, endochondral
ossification takes place during the regeneration of bone following injury (fracture callus).
2.1.1.3 Apoptosis
The size of a cell population depends on the balance between cell production and cell loss
(Kerr et al. 1972). In bone tissue, there is a fine balance between bone formation, bone
resorption, bone cell proliferation and apoptosis. This balance keeps the skeletal mass nearly
constant (Weinstein & Manolagas 2000). The rate of bone formation is mainly dependent on
the number of osteoblasts. Osteoblast number is determined by the rate of replication from
their progenitors and the lifespan of mature cells (Jilka et al. 1998).  The vast majority (50-
70%) of osteoblasts die of apoptosis (Jilka et al. 1999); the prevalence of osteoblast apoptosis
is regarded a major regulator of  bone formation (Jilka et al. 1999).
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Apoptosis is a basic biological mechanism that multicellular organisms use to remove
unwanted cells. The morphological phenomenon was first described by Kerr et al. (1972) to
include nuclear fragmentation and chromatin condensation, plasma membrane blebbing, cell
shrinkage and the eventual cell breakage into small membrane-surrounded fragments. These
fragments, apoptotic bodies, are cleared by phagocytosis by other cells, without inciting an
inflammatory response. In addition to removal of a cell, apoptosis gives rise to a number of
signal molecules that affect the behaviour of neighbouring cells (Noble 2003). The
morphological and biochemical changes associated with apoptosis are caused by activation of
intracellular cysteine proteases, caspases (Reed 2000). These proteases are in the form of
inactive zymogenes in virtually all animal cells. Their activation is triggered by proteolytic
cleavage to generate large (~20 kD) and small (~10 kD) subunits. The active enzyme is a
heterotetramer composed of two large and two small subunits, with two active sites per
molecule (Thornberry & Lazebnik 1998). Caspases are activated by their own cleavage at
aspartic acid, and after activation cleave their substrates at the aspartic acid residues. This
leads to a proteolytic cascade whereby activated enzymes activate themselves and each other
(Reed 2000). Ultimately, cell death is controlled by the balance between the apoptosis
inhibitor and promoter signals (Raff 1998).
Figure 3: Apoptosis signalling (from Xing and Boyce 2005). The extrinsic signalling pathway
(on the left) is triggered when a death ligand binds to the death receptor, which in turn cleaves
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pro-caspase 8, resulting in an active enzyme.  The intrinsic signalling pathway (on the right)
is activated by the release of cytochrome c from the mitochondria due to cellular stress.
Cytochrome c binds to Apaf-1, which in turn activates caspase 9. Selected factors promoting
osteoblast apoptosis are presented in text box I, and factors inhibiting osteoblast apoptosis are
presented in text box II.
Over a dozen caspases have been identified in humans, two-thirds of which may participate in
apoptosis (Hengartner 2000). If subgrouped from a functional perspective, it is useful to view
caspases as initiator (upstream) or effector (downstream) caspases. Initiator caspases are
activated in response to signals ordering the cell to die. The initiators pronounce the death
sentence, but the effector caspases are the true executioners that cleave the key proteins and
dismantle the cell (Barinaga 1998). Effector caspase activation is largely dependent on the
activation of initiator caspases.
Two complex caspase activation pathways exist the extrinsic and intrinsic pathways (Figure
3). A simplified description of extrinsic induction of apoptosis involves CD95, FADD (Fas-
associated death domain) and pro-caspase 8 proteins. The signalling pathway is triggered
when a CD95 ligand binds to the receptor, which in turn alters the intracellular parts of the
receptor to bind adapter protein FADD. FADD binds pro-caspase 8 and cleaves it, resulting in
an active enzyme.
Cells commit suicide not only when they receive signals from outside but also when a single
cell fails to work properly, such as in an incomplete cell-division cycle. The intrinsic caspase
activation pathway involves the release of cytochrome c from the mitochondria, thereafter
cytochrome c binds to an apoptotic protease-activating factor-1 (Apaf-1) protein. Apaf-1
cleaves the initiator caspase-9 zymogen to form an active enzyme. Bone cell apoptosis can be
promoted or inhibited by different stimuli. Alterations in the timing and extent of osteoblast
apoptosis could have a significant impact on the rate of bone formation (Jilka et al. 1998).
Furthermore, the lifespan of osteoclasts, osteoblasts and osteocytes is an important
determinant of bone mass and strength (Xing & Boyce 2005).
2.1.2 Osteoclasts
Osteoclasts are large multinucleated, bone-resorbing cells needed for the removal of mineral.
Osteoclast activity dictates the rate of bone resorption. Osteoclasts are formed by the fusion of
mononuclear progenitor cells (Teitelbaum 2000). These precursors are of haematopoietic
origin. Differentiation into mature osteoclasts requires macrophage colony-stimulating factor
(M-CSF) and receptors for activation of nuclear factor kappa B (NF-?B) ligand (RANKL)
(Teitelbaum 2000). These two osteoclast differentiation factors are essential for
osteoclastogenesis. Both are produced by osteoblasts and marrow stromal cells. M-CSF is a
secreted product that binds to its receptor, c-Fms, and allows early osteoclast precursors to
continue to mature. RANKL is a surface protein, which binds to RANK in cell-to-cell contact.
Binding of RANKL to RANK leads to the differentiation and maturation of osteoclast
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precursor cells to mature osteoclasts. This binding results in a cascade of events that includes
activation of NF-?B. Osteoclast formation and activity can be blocked by osteoprotegerin
(OPG) (Lacey et al. 1998). OPG is a soluble decoy receptor competing with RANK for
RANKL. When OPG binds to RANKL, it prevents it from binding to RANK, resulting in the
inhibition of osteoclast formation. Almost all of the bone-resorbing factors stimulate
expression of RANKL in osteoblasts/stromal cells (Suda et al. 1999). Three independent
signals have been proposed to induce RANKL expression in osteoblasts/stromal cells: vitamin
D receptor-mediated signals induced by 1,25(OH)2D3, cAMP/protein kinase A (PKA)-
mediated signals induced by PTH or PGE2, and gp130-mediated signals induced by IL-11
(Suda et al. 1999). Among these signals, vitamin D receptor- and cAMP/PKA-mediated
signals suppress OPG expression in osteoblasts/stromal cells.
2.1.3 Bone remodelling
Once bone formation (i.e. the acquisition of bone mineral density, BMD) has stopped
(somewhere about 28 years of age), peak bone mass (PBM) is maintained by remodelling.
Remodelling is a continuous process involving the breakdown and re-formation of bone, the
maintanance of maximal BMD and the repair of any damage (e.g. fractures). The adult
skeleton is completely regenerated every 10 years (Manolagas 2000).
Bone remodelling takes place in basic multicellular units (BMUs). The BMU is a unique
temporary anatomical structure that consists of a team of osteoclasts in front; a team of
osteoblasts behind and the associated blood vessels, connective tissue and nerves (Parfitt
1994). Each BMU originates in a particular place at a particular time, travels through or across
the bone surface towards its target and continues beyond this target for a variable distance
(Parfitt et al. 1996). The advance of a BMU continues for 6-9 months (Jilka 2003).
A BMU will originate after microdamage to the bone, mechanical stress, exposure to some
cytokines or at random. The initiation signals producing a BMU are not fully understood, but
osteocyte involvement has been suggested (Noble et al. 1997). The lining cells first become
active (in response to osteocyte signals) and change from a pancake-like shape to a cuboidal
form. Lining cells may then prepare the bone surface for osteoclast attachment (Manolagas
2000). Upon contact with bone, osteoclasts develop a polarized phenotype and attach firmly to
the surface (Fallon et al. 1983). The bone-facing plasma membrane forms a ruffled border,
sealed from the sides with a sealing zone. The resorptive process takes place in this isolated,
extracellular microenvironment at the osteoclast-bone interface. Osteoclasts produce acid to
promote mineral mobilization and to establish the pH optimum for lysosomal enzymes that
degrade the protein matrix (Blair et al. 1986, Blair et al. 1993). The most abundant protease
enzyme in osteoclasts is cathepsin K (Drake et al. 1996). Cathepsin K is regarded as a key
enzyme in the degradation of organic bone matrix (Morko et al. 2005). Excessive cathepsin K
enhances bone resorption and leads to osteopenia of trabecular bone and increased porosity of
cortical bone (Morko et al. 2005, Kiviranta et al. 2001). The average lifespan of an osteoclast
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is about 12 days, after which it undergoes a programmed cell death, known as apoptosis (Jilka
2003).
Figure 4: Bone remodelling. A) Osteoclast precursor cells have a receptor for RANKL .
Osteoblast precursor cells have a ligand for RANK       . B) Upon binding RANKL, osteoclast
precursors differentiate into mature bone-resorbing osteoclasts. C) Mature bone forming
osteoblasts secrete RANKL decoy receptor OPG        , which inhibits osteoclast
differentiation and function. D) Some of the osteoblasts become entrapped in the newly
synthesized matrices and further differentiate into osteocytes.
As the BMU wanders, new osteoclasts are continuously activated and then start resorption. At
any site on the surface, the resorption lasts about two weeks. The coordination of osteoblast
and osteoclast differentiation, cell function and cell death is essential for the maintenance of
normal bone homeostasis. IGF-I is a candidate for the coupling factor in bone resorption and
formation (Rubin et al. 2002). The development of mature osteoblasts at the BMU is
promoted by growth factors released from the bone matrix during resorption, as well as by
growth factors produced by osteoblast progenitors themselves. The active, secreting
osteoblasts make layers of osteoid, slowly refilling the cavity, and, as the osteoid thickens it
begins to mineralize (Figure 4). Mineralization, also, is regulated by the osteoblasts. The
osteoblasts are less efficient at making bone than the osteoclasts are at removing it, and hence,
any factor causing a higher rate of bone remodelling will ultimately lead to a more rapid loss
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of bone mass and more fragile bones. Bone loss caused by sex steroid deficiency or
glucocorticoid excess is caused by alteration of bone cell production by prolonging osteoclast
lifespan and shortening osteoblast lifespan. The average lifespan of an individual matrix-
synthesizing osteoblast varies from a few days to about 100 days (Jilka 2003). During bone
remodelling the osteoblast lifespan is estimated to be 6-8 days (Jilka et al. 1998). The final
osteoblasts turn into lining cells, osteocytes or die of apoptosis.
2.2 Bone strength and quality
Weak bones fracture easily. Osteoporosis is a disease characterized by low BMD and
increased fracture risk. Bone strength is a combination of structural, geometric and material
properties (van der Meulen et al. 2001). Bone size, shape and particulalarly mass are
important determinants of bone strength (Heaney et al. 2000). Big bones have higher absolute
strength than small bones, but their relative strength can be identical if the material properties
are equal. The most important material property of bone is the mineral content; the more
mineral in the bone, the greater the stiffness and ultimate strength (Seeman 2003). Bone
toughness is determined by collagen content (Currey 2003); decreased collagen in bone
reduces toughness (Seeman 2003).
Bone mineral content can be measured by dual-energy x-ray absorptiometry (DXA). The
measurement provides two-dimensional areal BMD. DXA measurement is widely used in
clinical assessment of BMD and individual fracture risk. Peripheral quantitative computed
tomography (pQCT) gives three-dimensional volumetric BMD. pQCT discriminates between
cortical and trabecular bone, and the results provide more information for research purposes
than DXA. Microtomography (micro-CT) also gives three-dimensional information on bone.
Micro-CT scans bone trabeculae and even bone resorption sites.
Bone mechanical strength is probably the most important parameter related to fracture risk
(Peng et al. 1994). Animal models are used for the mechanical testing of bone, which requires
applying force until bone breaks. The tibia bending test provides information on cortical bone
material properties, and the mechanical test for the femoral neck is used to measure
cancellous bone properties (Ruhmann et al. 2006). In cancellous bone, the overall structure
seems to be more important than the material properties (Currey 2003).
Bone quality generally refers to the effects of skeletal factors that contribute to bone strength
but are not accounted for by measures of bone mass (Hernandez & Keaveny 2006). The
amount of bone turnover influences bone strength. A sufficient amount of turnover is needed
to replace old bone with new bone. However, the remodelling process itself is a source of
structural weakness (Heaney 2003). With high remodelling, older bone accumulates
microdamage (Schaffer 2003) and younger bone becomes undermineralized. Microdamage
accumulation reduces bone stiffness (Noble 2003). Excessive remodelling will eventually
lead to bone loss, trabecular thinning, loss of connectivity, cortical thinning and porosity
(Bourrin et al. 2000, Seeman 2003). In the regions of high tissue strain, resorption cavities
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reduce the strength and stiffness of the bone independent of their effect on bone volume
(Hernandez et al. 2006).
2.3 DIET
2.3.1 Diet and bone
Nutrition is important for optimizing bone health throughout life. The dietary components
most widely studied and regarded as relevant to bone health are calcium and vitamin D.
Several other nutrients also play a role in bone health, including minerals, such as phosphorus
and magnesium, micronutrients, such as vitamin K and vitamin C, and macronutrients, such
as protein. Because bone is a complex living tissue, examining nutrients individually may
yield misleading. Nutrients are found together in foods, and associations attributed to a single
nutrient may, in fact, be caused by a more complex constellation of nutrients consumed
contemporaneously (Tucker et al. 2002). In addition to sufficient intake of specific nutrients,
food groups (e.g. fruit and vegetables) seem to have a positive effect on bone health (New et
al. 2000, Tucker et al. 2002, MacDonald et al. 2004, Okubo et al. 2006). Eating pattern can
affect the intake of nutrients that build bones. For example, calcium is absorbed by an active
saturable system that is affected by the source and amount of calcium. Calcium bioavailability
from plant foods is reduced if the plant contains a calcium absorption inhibitor such as oxalate
or phytate (Weaver et al. 1999).
Eating frequency also plays another role besides the absorption of nutrients. In a rodent model,
frequent small meals increased total bone mineral content, trabecular bone mineral density
and cortical thickness, and markedly reduced the decrease in these parameters in aged rats (Li
& Muhlbauer 1999). Gastrointestinal hormones released after a meal are also involved in
regulating bone turnover (for review see, Clowes et al. 2005). Hormones, such as glucagon-
like peptide (GLP)-1 and -2, have been reported to cause immediate reduction in bone
resorption after a meal (Henriksen et al. 2003). Gastric inhibitory polypeptide (GIP), another
gastrointestinal hormone, has receptors in osteoblasts (Bollag et al. 2000). GIP increases bone
formation by increasing collagen I synthesis and ALP activity in osteoblasts (Bollag et al.
2001) and by reducing osteoblast apoptosis (Tsukiyama et al. 2006). Figure 5 summarizes the
dietary factors affecting bone health.
The positive effects of foods or nutrients may be addressed through a nutritional pathway or
modulation of other factors affecting bone health. Examples of such nutritional effects include
the hormonal functions of phytoestrogens, reduced risk of falls due to the individual’s
increased alertness in response to the substance (e.g. caffein), and the influence of food
components, such as bioactive peptides, on gene expression. A Western-style diet that is low
in calcium, vitamin D and folic acid and high in fat may result in low bone mass and poor
bone quality, leading to an increased risk of a fragility fracture. Ward et al. (2003) have
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shown that Western-style diets have a negative effect on femur BMC and biomechanical
strength properties in a rodent model.
Figure 5: Dietary factors affecting bone health.
2.3.2 Nutrients and gene expression
Individual variation in gene expression is a combination of genetic polymorphisms,
physiological variations (such as time of day and gender) and environmental factors
(Hamilton 2002). Diet is an environmental factor affecting gene expression through
epigenetic modification (Jaenish & Bird 2003). Epigenetic information is heritable during cell
division, but it is not contained within the DNA sequence itself, hence the name meaning
‘outside conventional genetics’. Epigenetic processes are mediated by DNA methylation and
histone modifications (Jaenish & Bird 2003). Studies with monozygotic twins help to estimate
the size of the contribution of genetic and environmental factors to the natural variation in
gene expression. Phenotypic differences within monozygotic twin pairs are due to
environmental effects alone, as these individuals uniquely share their entire genetic
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background (MacGregor et al. 2000). Fraga et al. (2005) examined gene expression among  3-
to-74-year-old twin pairs using microarray technology. They found that although 3-year-olds
had nearly identical expression profiles, the 50-year-old twins had very different profiles. The
key message of this study was that epigenetic modifications in monozygotic twin pairs
diverge as they become older, with this difference most likely being explained by both
internal and external factors (Fraga et al. 2005). Environmental factors, such as diet, can
modify the epigenetic states and contribute to the formation of the phenotype (Jaenish & Bird
2003).
Nutrients regulate gene expression by direct and indirect mechanisms. Direct interaction with
transcription factors controlling specific genes involves cis-regulatory elements in the
promoter region. Most nutrients function by regulating the secretion or intracellular action of
hormones, which in turn alter gene expression (De Caterina & Madonna 2004). Macro- and
micronutrients regulate the overall cell metabolic functions by controlling their own
metabolism (e.g. glucose - insulin) and changing the phenotypic response to the environment
(e.g. vitamin A - variety of genes). Biological processes can be finely tuned by nutritional
interventions in order to restore appropriate biological responses. This kind of nutrigenomics
is a scientific investigation of the effects of nutrients in the body on each of us as individuals.
The future of nutrition might involve diets tailored to suit a person’s genetic make-up,
including nutraceuticals (also referred to as phytochemicals or functional foods) with health-
promoting, disease-preventing or medicinal properties.
A balanced diet, adequate energy and nutrient intake form the foundation for all tissue
development, including bone. Optimal nutrition enables maximal PBM development and
maintains the bone mass achieved. As bone can be influenced by diet, nutrients important for
bone growth should be recommended, but greater awareness regarding bone-impairing
nutrients is also needed (Ward et al. 2003). Dietary phosphate, protein, and bioactive peptides
will be discussed in more detail below.
2.3.3 Phosphate and bone cells
Phosphorus is the second most abundant element (after calcium) present in our bodies; 85% is
found in the bones and teeth. Calcium and phosphorus work together in bone formation, with
the Ca:P ratio in human bone being approximately 1.5:1 (w:w) (European Food Safety
Authority 2005) hence inorganic phosphate (Pi) is a necessary component of hydroxyapatite.
Pi functions also as a signalling molecule (Beck 2003). Osteoclasts and osteoblasts both have
Na-Pi transporters.
Pi is integral to bone remodelling and osteoblast function during the differentiation process
(for review, see Beck 2003). Increased intracellular Pi upregulates osteoblast genes involved
in cell cycle, proliferation and energy metabolism (Conrads et al. 2005). As osteoblast
differentiation proceeds, the levels of ALP enzyme rise. ALP is responsible for the locally
increased Pi levels and the initiation of mineralization. Osteoblast Na-Pi transporter activity
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can be upregulated by PTH. An experiment on UMR-106 cells showed 10-7 M PTH to
stimulate the Na-Pi transport (Seltz et al. 1989). Similarly, intermittent administration of PTH
stimulates osteoblast proliferation and differentiation (Dempster et al. 1993, Swarthout et al.
2001).
Phosphate participates in the remodelling process. At bone resorption site, osteoclasts
dissolve the bone matrix and release calcium- and phosphate-ions. A relatively small increase
in the amount of calcium (0.1-1 mM) together with Pi causes osteoblast apoptosis (Adams &
Shapiro 2003). Osteoblast apoptosis occurs most frequently at the sites of active bone
resorption (Adams & Shapiro 2003). As bone resorption proceeds, increasing concentrations
of Pi suppress osteoclasts (Kanatani et al. 2003). In vitro high Pi concentration (2.5-4 mM)
inhibits osteoclast formation and bone resorption by mature osteoclasts (Kanatani et al. 2003).
Pi inhibits osteoclast maturation by direct action and via osteoblasts by the upregulation of
OPG (Kanatani et al. 2003). The increase in osteoblast differentiation and decrease in
osteoclast formation and activity by Pi promotes local bone formation stimultaneously
blocking bone loss.
In vivo Katsumata et al. (2005) have shown a high phosphate diet to stimulate osteoblast
RANKL mRNA expression through elevated PTH concentration. The increase in
RANKL/OPG ratio enhances osteoclastogenisis and results in an increased osteoclast number,
causing bone loss via increased bone turnover.
2.3.4 Dietary phosphate and bone
Phosphorus functions as a limiting nutrient in the biosphere. A common feature of such
nutrients is efficient absorption; phosphate absorption is 60-80% remaining unchanged even
at high intakes (Draper et al. 1972, for review, see Lemann & Favus 2003). Dietary
phosphorus is predominantly found as phosphate (PO43-).  Phosphate absorption occurs in the
small intestine via a transcellular pathway that is dependent on sodium (Na- Pi  cotransport)
(reviewed in Cross et al. 1990). A low-phosphate diet and vitamin D3 increase brush-border
Na- Pi cotransporter in the small intestine (Hattenhauer et al. 1999). Phosphate homeostasis
and plasma concentration are maintained by the kidneys. Most of the phosphate is excreted
into the urine. Phosphate reabsorption takes place in the proximal tubule and is mediated by
Na-Pi co-transporter type IIa (Npt2a) (for review, see Tenenhouse 2005). Phosphate
reabsorption is increased by factors such as a low dietary phosphate intake, insulin-like
growth factor (IGF)-I and 1,25-dihydroxyvitamin D3, whereas PTH and fibroblast growth
factor (FGF)-23 inhibit phosphate reabsorption, resulting in phosphaturia.
In human nutrition, phosphate is widely distributed in many foods (Heaney 2004), and is thus
no longer a limiting nutrient. The main sources of intake for phosphate in the Finnish diet are
milk and milk products (35%), bread and cereal (30%) and meat and eggs (18%) (National
FINDIET 2002 Study). Convenience foods and soft drinks also contribute to the phosphate
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intake in the form of phosphorus-containing food additives. Already in the late 1970s food
additives accounted for 20-30% of adult phosphorus intake (Calvo 1993). Because the
nutrient composition databases used in calculating mineral intakes do not take into account
phosphorus-containing food additives, intakes are likely to be underestimated (Calvo 1993).
The recommended dietary allowance (RDA) for phosphate in Finland (600 mg/d for adults,
Finnish Nutrition Recommendations 1999) is exceeded on average by two- to threefold
(Findiet 2002). The average dietary calcium to phosphate ratio in Finnish diet is 1:2 for
women and 1:3 for men. Because phosphorus is abundantly distributed in the food supply and
is well absorbed, dietary phosphorus deficiency is extremely rare (Institute of Medicine 1997).
Dietary phosphate deprivation leads to rapid breakdown of the skeleton (e.g. Kanatani et al.
2003). At the cellular level, bone formation processes are inhibited and bone resorption is
stimulated. In vivo high dietary phosphate intake has been shown to cause bone loss in a
variety of animal models (Calvo & Park 1996). Studies in rodents (mice and rats), rabbits,
pigs, dogs and primates show high dietary phosphate diet to elevate serum PTH, stimulate
bone resorption, and to cause bone loss and osteopenia (Calvo & Park 1996).
2.3.5 Dietary protein and bone
Protein accounts for one-third of bone mass, making it one of the most protein-dense tissues
of the body. Nevertheless, high dietary protein intake has been claimed to have detrimental
effects on bone health (for review, see Ginty 2003). A proposed underlying mechanism is that
increased protein intake increases acid production due to the hepatic oxidation of sulphur-
containing amino acids such as methionine, cysteine and cystine (Rizzoli & Bonjour 2004).
This would be the case in renal diseases, where a high-protein diet will cause metabolic
acidosis as the renal response to excrete excess acid is reduced. The consequential reduction
in blood pH increases bone resorption and urinary calcium loss (Krieger et al. 2004). Bone
resorption is increased since reduction in pH increases osteoclast formation and activity and
reduces osteoblast collagen synthesis and mineralization (Arnett et al. 1994, Lehenkari et al.
1998, Arnett 2003).
The in vivo studies showing high dietary intake to increase bone resorption in healthy subjects
are often carried out using high doses of purified forms of protein. In mixed diets the dietary
alkali load (fruit and vegetables) has been shown to neutralize the pH-lowering effects (for
review, see Ginty 2003). Furthermore, there is no definitive evidence that high protein intake
increases renal calcium excretion in healthy subjects. In fact, dietary protein increases
intestinal calcium absorption (Kerstetter et al. 2005), whereas low protein intake reduces
calcium absorption and results in elevated serum PTH (for review, see Ginty 2003). The
recommended amount of protein for healthy adults is 15-20 energy% or 0,8–1 g/kg body
weight (Finnish Nutrition Recommendations 2005).
Many studies have found an overall beneficial relationship between high dietary protein and
bone health (Hannan et al. 2000, Hoppe et al. 2000, Whiting et al. 2002, Kerstetter et al. 2003,
Bowen et al. 2004, Wengreen et al. 2004, Alexy et al. 2005). Dietary protein has a positive
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correlation with bone area (Hoppe et al. 2000) and BMD, and a negative correlation with
fracture rate (Hannan et al. 2000, Dawson-Hughes & Harris 2002). Dietary protein plays an
important role in bone strength (Oxlund et al. 1995, Wengreen et al. 2004), as it is essential
for bone turnover and matrix formation (Oxlund et al. 1995, Heaney 2002). Furthermore,
protein supplementation has been proven to aid fracture repair in hip fracture patients (Delmi
et al. 1990).
The osteotrophic effects of protein are partly explained by enhanced IGF-I production and
action (Thissen et al. 1994, Bonjour 2005). IGF-I is an essential mediator of tissue anabolism
(for review, see Ginty 2003). It increases osteoblast activity and type I collagen production
and acts as a coupling factor for bone resorption and formation (Rubin et al. 2002).
Furthermore, IGF-I is essential for longitudinal bone growth, as it stimulates the proliferation
and differentiation of chondrocytes in the epiphyseal plate. However, in a rodent model, a
protein-restricted diet with normalized IGF-I by infusion failed to promote growth, indicating
adequate protein intake to have positive effects in addition to increased IGF-I (Thissen et al.
1994). Adequate protein intake should be recommended in the maintenance of bone integrity
and in the prevention and treatment of osteoporosis (Bonjour 2005).
2.3.6 Bioactive peptides and bone
Peptides are short chains of amino acids produced in the hydrolysis of proteins by
gastrointestinal enzymes or by microbiological fermentation. A small proportion of these
peptides are resistant to further degradation and possess biological function beyond being
tissue-building blocks. These peptides are called bioactive peptides. Some of these peptides
express activity in the intestine (Shimizu 2004), others after absorption (Satake et al. 2002).
Two human di-/tri-peptide transporters have been identified, hPepT1 and hPepT2 (for review,
see Nielsen & Brodin 2003). hPepT1 is expressed in the small intestine, whereas both hPepT1
and hPepT2 are expressed in the proximal tubule.
Bioactive peptide actions vary; opioid peptides are opioid receptor ligands and modulate
absorption processes in the intestinal tract, angiotensin-I-converting enzyme (ACE)-inhibitory
peptides function as hemodynamic regulators and exert an antihypertensive effect, casein
peptides are immunomodulators and stimulate the activities of cells of the immune system,
antimicrobial peptides kill sensitive microorganisms, antithrombotic peptides inhibit
aggregation of platelets, and caseinophosphopeptides may function as carriers for different
minerals, especially calcium (Froetschel et al. 2001, Aimutis 2004, FizGerald et al. 2004).
Peptides remaining functional after absorption are typically 2-5 amino acids in length and
have a proline residue in the C-terminus (Curtis et al. 2002). This structure is common among
food-derived tripeptides such as Ile-Pro-Pro (IPP), Val-Pro-Pro (VPP) and Leu-Lys-Pro
(LKP). Food-derived bioactive peptides are claimed to be health-enhancing components of
functional food and pharmaceutical preparations (Meisel & Bockelmann 1999). Estimates of
peptide consumption are difficult to obtain because of the wide variation in concentrations
(Bernard 2005). However, in Japan it is estimated that the mean intake from tripeptide-
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enhanced products is 0.005 mg/kg body weight/day and in United States 0.1 mg/kg body
weight/day (Bernard 2005).
Another application for the use of bioactive peptides is the development of biomaterials for
tissue engineering. The surface modification of biomaterials with bioactive molecules is a
simple way to make biomimetic materials, i.e. materials elicting specific cellular responses
and directing new tissue formation (Lutolf et al. 2003). The early biomaterial work has been
done on long ECM proteins, such as fibronectin and lamin, which promote cell adhesion and
proliferation. Since the several amino acids long signalling domains were found along the
long chain of ECM proteins, these fragments have been used for surface modification in
numerous studies (for review, see LeBaron & Athanasiou 2000). These amino acids interact
with cell membrane receptors. The short peptide sequences are more stable and can be
synthesized more economically than long proteins. Materials such as glass, quartz, metal
oxide and polymers have been modified with peptides and characterized for cellular
interaction with their surfaces. The most commonly used peptide for surface modification is
the Arg-Gly-Asp (RGD) amino acid sequence derived from fibronectin. RGD serves as a
primary cell attachment cue (for review, see Schaffner & Dard 2003). Osteoblasts have
integrin receptors which bind RGD (reviewed in Schaffner & Dard 2003). This binding site is
involved in cell morphology, differentiation, proliferation, gene expression, cell survival and
apoptosis. The RDG application in tissue engineering uses the same pathways that take place
in bone remodelling in vivo. As osteoclasts resorb bone, minerals are dissolved and matrix
proteins are degraded into amino acid sequences. Some of these sequences, such as RGDS
and GRGDSP (Adams & Shapiro 2003), cause osteoblast apoptosis and clear the way for
osteoclasts and some of the peptides, such as RDG, to promote osteoblast cell attachment,
proliferation, differentiation and mineralized matrix formation. Furthermore, RGD peptide
inhibits bone resorption; hence, local bone formation can efficiently repair the resorption pit
(for review, see Schaffner & Dard 2003). The fact that peptides containing the RGD motif
arrest osteoclastic bone resorption in vitro (Horton et al. 1991) suggests such agents may also
blunt bone resorption in vivo (Engelman et al. 1997).
Integrin receptors are not the only mechanism of action for peptides to modulate osteoblast
function. The extracellular calcium-sensing receptor (CaR) plays an important role in the
regulation of calcium homeostasis. CaR is widely expressed in many tissues, including bone.
Several osteoblastic cell lines have been found to express CaR (Yamauchi et al. 2005), but
there is still debate whether all osteoblasts possess CaR (Pi et al. 2005). Although calcium is
the physiological ligand for CaR, other divalent and trivalent cations can also activate this
receptor (Pi et al. 2005). In addition, CaR activity (in the presence of Ca2+) is modulated by
amino acids (Conigrave et al. 2000) and small peptides (Quinn et al. 1997). The CaR
regulates bone turnover by stimulating osteoblast proliferation (Yamaguchi et al. 1998) and
differentiation (Yamauchi et al. 2005). The CaR also modulates chondrogenic cell matrix
production and mineralization (Chang et al. 2002). Because the CaR can integrate signals
arising from distinct classes of nutrients i.e. mineral ions and amino acids, the actions of
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amino acids on the CaR may provide explanations for several long-recognized but poorly
understood effects of dietary protein on calcium metabolism (Conigrave et al. 2000). The
CaR might also be a mechanism of action for bioactive peptides.
2.4 PARATHYROID HORMONE (PTH)
2.4.1 PTH metabolism
Parathyroid hormone (PTH) is a single-chain polypeptide with 84 amino acids. The hormone
is generated by the chief cells of the parathyroid glands and released into circulation. PTH(1-
84) is further cleaved to generate shorter fragments. The N-terminal 1-34 fragment of the PTH
mediates full PTH activity.
PTH functions as the principal regulator of calcium homeostasis (Figure 6). Parathyroid cells
have calcium-sensing receptors (CaRs). The CaR is negatively coupled to PTH release (for
review, see Kifor et al. 2002). The parathyroid cell is sensitive to changes in extracellular
calcium concentrations, with small increases in extracellular calcium inhibiting secretion of
PTH. Conversely, a decrease in extracellular calcium leads to a rapid increase in PTH
secretion.
Figure 6: PTH regulates extracellular calcium. Parathyroid cells respond to decreased serum
calcium and/or increased serum phosphate by increaseing PTH secretion. PTH increases
calcium reabsorption from the renal tubules, stimulates renal 1,25(OH)2D3 production and
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intestinal calcium absorption. PTH stimulates bone resorption by increasing the number and
activity of osteoclasts. As a result serum calcium is returned to normal.
Phosphate also has a direct action on the parathyroid gland, although the mechanism remains
somewhat obscure. High phosphate concentration inhibits arachidonic acid production in the
parathyroid tissue, which in turn stimulates PTH secretion (Almadén et al. 2000). A high-
phosphate diet induces parathyroid cell proliferation (Roussanne et al. 2001) and PTH
secretion, causing serum PTH levels to rise (Almadén et al. 1996, 1998, Kärkkäinen &
Lamberg-Allardt 1996, Miyamoto et al. 1998, Koshihara et al. 2001).
An increase in phosphate intake can lower serum ionized calcium, which further enhances
PTH secretion (for review, see Lemann & Favus 2003). Reducing dietary phosphorus intake
reduces PTH (Rodriguez 1999). High dietary phosphate intakes might also form insoluble
salts in the intestinal lumen and reduce calcium absorption (e.g. Masuyama 2003). However,
according to the Institute of Medicine (1997), phosphorus does not appear to negatively affect
calcium absorption. Moreover, while the intake ratio of calcium to phosphorus is relevant
during infancy and periods of rapid growth, it is not important in adulthood (Institute of
Medicine 1997). The principal target organs for PTH are the kidney (increasing proximal
tubular resorption of calcium, phosphate excretion and 1,25 dihydroxyvitamin D formation)
and the skeleton (for review, see Swarthout et al. 2002).
2.4.2 PTH and bone metabolism
Osteoblasts are the primary target cells for the effects of PTH on bone tissue. For long it was
believed that osteoblasts express the PTH1 receptor, while osteoclasts do not (Partridge et al.
1981, Suda et al. 1996). However, recent findings indicate that osteoclasts also have PTH1
receptors (Dempster et al. 2005). For a review on PTH1 receptor structure and function, see
Chorev (2002). PTH effects on osteoblasts are mediated via binding of PTH to the seven
membrane-spanning G protein–coupled receptor and activation of either the protein kinase A
(PKA) pathway or the protein kinase C (PKC) pathway (Kronenberg et al. 1998).
The PKA pathway is mediated via Gs subunit and it involves adenylate cyclase activation,
followed by cAMP formation, and PKA activation (Turner et al. 2000). This pathway is
activated in PTH’s anti-apoptotic function but also in RANKL production (Bellido et al.
2003). The PKC pathway is mediated via Gq subunit (Turner et al. 2000). Gq activates
phospholipase C (PLC), leading to the formation of  diacylglycerol (DAG) which activates
protein kinase C (PKC) and 1,4,5-inositol triphosphate (IP3), resulting in increased
intacellular Ca2+ . The proliferative response of osteoblasts to PTH is mediated by the PKC
pathway (Swarthout et al. 2001).
PTH-related peptide (PTHrP) is another molecule known to act on the same PTH1 receptor as
PTH (Juppner et al. 1991, Lanske et al. 1998) and capable of increasing bone mass when
administered intermittently (Hock et al. 1989, Caulfield et al.1990). PTH can be regarded as
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the hormone to regulate calcium homeostasis by promoting bone resorption, whereas PTHrP
functions as a bone cytokine to control bone mass (Martin 2005). Mesenchymal cells
differentiating into osteoblasts produce PTHrP at  an early stage, with decreasing levels as
cells mature. PTH1 receptor is expressed at a later stage of pre-osteoblast differentiation
(Martin 2005). PTHrP acts on PTH1 receptor-positive pre-osteoblasts and the cells further
differentiate into mature osteoblasts. Osteoblasts can synthesize PTHrP in response to PTH
(Walsh et al.1997). This locally produced PTHrP is important for the orderly commitment of
precursor cells towards the osteogenic lineage and for their maturation and function (Miao et
al. 2005). Furthermore, PTHrP prevents osteoblast and osteocyte apoptosis and promotes
osteoclast formation (Miao et al. 2005). Within the skeletal microenvironment, PTHrP
regulates bone turnover by potentiating bone formation (Miao et al. 2005). Prolonged
stimulation of preosteoblasts by PTHrP increases RANKL production and osteoclast
formation (Martin 2005). In vitro study by Kaji et al. (1995) revealed that the C-terminal
PTHrP peptide fragments stimulate osteoclast formation in bone cell cultures containing
osteoblasts, but not the bone resorption by mature osteoclasts. Previous studies by Fenton et al.
(1991, 1994) reported the same PTHrP fragment (107-111) to inhibit osteoclast formation and
resorption. The discrepancy could be due to different culture conditions and species.
PTH can promote both the formation and resorption of bone. Elevated levels of PTH increase
bone turnover, leading to either anabolic or catabolic effects on the skeleton depending upon
the pattern and duration of elevation (for review, see Poole & Reeve 2005).
2.4.2.1 Anabolic effects of PTH on bone
Intermittent administration of human PTH increases bone mass (Black et al. 2003, Arita et al.
2004). Anabolic effects require brief exposures to higher-than-average PTH concentrations.
Intermittent stimulation by PTH promotes bone formation on the periosteal, endocortical and
trabecular surfaces, increasing cortical and trabecular thickness and trabecular connectivity
(Jiang et al. 2002). PTH also affects bone microarchitecture by shifting trabecular structure to
a more plate-like appearance (Jiang et al. 2002).
PTH increases bone formation by stimulating the proliferation and differentiation of
osteoblast precursors (Dempster et al. 1993, Swarthout et al. 2001), promoting osteoblast
protein synthesis (Swarthout et al. 2001) and increasing osteoblast lifespan by preventing
osteoblast apoptosis (Jilka et al. 1999). Intermittent administration of PTH stimulates bone
formation by preventing osteoblast apoptosis, hence osteoblast matrix synthesis is prolonged
(Jilka et al. 1999). The anti-apoptotic effect requires the hormone to bind to the PTH/PTHrP
receptor. Osteoblasts uniformly produce cAMP in response to PTH, though it is likely that the
anti-apoptotic signal is mediated by cAMP (Jilka et al. 1999). Contrary to several other
studies (Calvi et al. 2001, Xing & Boyce 2005), Jilka et al. (1999) did not confirm PTH to
increase bone formation through stimulating osteoblast progenitor cell proliferation or bone
lining-cell hypertrophy and to resume matrix synthesis.
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2.4.2.2 Catabolic effects of PTH on bone
Continuously high levels of PTH reduce BMD. Such continuous secretion of PTH (as that
occuring in primary hyperparathyroidism) can lead to bone destruction. In vitro studies on cell
cultures indicate the deleterious effects of PTH on bone to be mediated by increases in the
number and activation of osteoclasts (Lee & Lorenzo 1999, Khosla 2001, Huang et al. 2004)
and increased osteoblast apoptosis (Fujimori et al. 1992, Turner et al. 2000). In vivo
continuous PTH administration does not appear to increase osteoblast apoptosis (Bellido et al.
2003). Generally, continuous PTH treatment of osteoblasts results in decreased expression of
many of the genes involved in bone formation (type I collagen, ALP, osteopontin,
osteonectin), while simultaneously increasing the expression of some of the genes involved in
bone resorption (collagenase-3, IL-6, IGF-1) (for review, see Swarthout et al. 2002). In
addition to increased collagenase expression and decreased collagen synthesis, PTH has a
direct stimulatory action on human osteoclasts mediated by PTH1R (Dempster et al. 2005)
and also an indirect effect via osteoblasts (reviewed in Teitelbaum 2000). Continuous
stimulation by PTH results in an increase in RANKL and M-CSF expression, production of
IL-6, and a decrease in OPG expression, leading to osteoclastogenesis (Ma et al. 2001,
Locklin et al. 2003) and increased bone resorption.
Figure 7: PTH has anabolic and catabolic effects on bone depending on the exposure.
Continuously high s-PTH leads to increased turnover and bone destruction.
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Bellido et al. (2003) have a mechanistic explanation for the opposite effects of PTH when
administered intermittently and continuously. PTH acting through PKA prevents osteoblast
apoptosis by inactivating proapoptotic Bad and transcription of survival genes, like Bcl-2. The
transcription factors of cAMP response element-binding protein (CREB) and Cbfa1/Runx2
mediate the survival gene transcription. However, PTH also promotes the degradation of
Cbfa1/Runx2. Continuous exposure to PTH leads to decreased level of Cbfa1/Runx2. This
provides a negative feedback loop to diminish the anti-apoptotic effects of PTH. As PTH
exposure continues, anti-apoptotic signals fade and osteoclastogenetic signals arise. Thus,
repeated brief exposures to PTH promote osteoblast accumulation, but continued exposure
tips the balance the other way and osteoclasts gain the upper hand (Figure 7).
2.4.3 PTH and Wnt signalling pathway
PTH regulates the expression levels of components of the Wnt pathway (Onyia et al. 2001),
hence Wnt signalling might play a role in the bone response to PTH. PTH induces the
expression of Fz1 and downregulates Dkk1, the Wnt antagonist (Kulkarni et al. 2005). The
downregulation of Dkk1 could lead to increased signalling through LRP5 and an anabolic
action on bone (Kulkarni et al. 2005). This conclusion is supported by the finding that PTH
increases β-catenin accumulation (Kulkarni et al. 2005). Furthermore, in addition to
promoting osteoblastogenesis, intermittent PTH inhibits adipogenesis (Rickard et al. 2006).
This finding gives support to the involvement of the Wnt pathway since osteogenic and
adipogenic differentiation from MSC have an inverse relationship, and the Wnt pathway
inhibits adipogenesis. However, the effect of PTH on Wnt and LRP5 signalling is not clear, as
a study with LRP5-/- mice shows intermittent treatment with PTH to increase cortical
thickness (Sawakami et al. 2006). Hence, PTH does not require LRP5, but functions via a
different signalling pathway (Sawakami et al. 2006).
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3 AIMS OF THE STUDY
This study aimed to shed light on the mechanisms of high dietary phosphate intake on bone and
to examine the influence of three bioactive tripeptides on osteoblast function and gene
expression. The in vivo results contribute to a greater understanding of the role of dietary
phosphate in bone health and the site-dependent effect of PTH. The in vitro results help
explain how bioactive peptides affect osteoblasts and human mesenchymal stem cells and
elucidate the mechanisms by which dietary protein supports bone health at the cellular level.
Specific aims were as follows:
1) To clarify the effect of a modest but prolonged increase in dietary intake of inorganic
phosphate on bone quantitative factors in mature male rats (Study I).
2)  To investigate the influence of high dietary phosphate intake on bone homeostasis and
structure and on bone cells in intact growing male rats (Study II).
3) To specify the effects of IPP, VPP and LKP tripeptides on osteoblast proliferation in
vitro and to clarify their function on gene expression (Study III).
4) To identify the long-term effect of IPP tripeptide on osteoblast gene-expression and
differentiation by using the qPCR method (Study IV).
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4 MATERIALS AND METHODS
Materials and methods are described briefly here. The detailed descriptions can be found in
the original publications (I-IV).
4.1 Experimental design for in vivo studies (Studies I and II)
Male Wistar rats (HsdBrlHan:WIST) were housed in groups of two, three, or five in plastic
cages at 21°C, 60 ± 10% humidity, and with a 12-h light/dark cycle. Access to water was ad
libitum.  Rats were offered 20 g of pellets daily of one of the diets varying in
calcium:phosphate ratios. The control diet contained 0.6% phosphate (Ca:P 1:1), and other
two diets, Ca:P 1:2 and Ca:P 1:3, contained 1.2% phosphate and 1.8% phosphate, respectively.
The calcium content in all diets remained constant at 0.6%. Rats continued with the diets for 8
weeks. Detailed diet compositions are shown in original publications I and II. All diets were
provided by the same supplier (Harlan Teklad, Madison, WI, USA). All study protocols were
approved by the Ethics Committee for Animal Experimentation at the University of Helsinki.
4.1.1 Assessment of bone measurements
4.1.1.1 Dual-energy X-ray bone densitometry (DXA)
In Study I, we measured right femur and lumbar spine (L4-6) and in Study II right femur bone
area (cm²), bone mineral content (BMC, g) and bone mineral density (BMD, g/cm²) in vivo
with a DXA device (Lunar PIXImusTM, GE Medical Systems, WI, USA) at onset as well as at
the end of the 8-week study period.
4.1.1.2 Bone mineral content
In Study I, tibia calcium and phosphate contents were analysed with an inductively coupled
plasma-mass spectrometer (ICP/MS, Perkin-Elmer Sciex Elan 6000, USA) using Quantitative
Analysis techniques.
4.1.1.3 Peripheral quantitative computed tomography (pQCT)
In Study II, tomographic measurements of the right femurs were performed with pQCT
(XCT540 Stratec; Norland Medical Systems, Pforzheim, Germany), and Stratec Software
version 5.40 was used to analyse the images at the distal metaphysis and femur midshaft.
4.1.1.4 Microtomography (micro-CT)
Six tibias were scanned in a micro-CT system (Skyscan 1172, Skyscan N.V., Aartlesaar,
Belgium) to obtain the three-dimensional bone structure of cortical and trabecular bone.
4.1.1.5 Mechanical testing
Right femurs and tibias were mechanically tested. The failure load of the femoral neck and
the three-point bending strength of the tibial shaft were measured according to Peng et al.
(1994, 1999) with a materials testing machine (1994). Stress and strain were calculated at
yield, maximal and fracture points in the testing curves according to Turner & Burr (1993).
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Following the bending test, horizontal and vertical (testing force direction) diameters were
measured with a micrometer at the outer (A, B) and inner (a, b) parts of the tibia fracture site.
The cross-sectional moment of inertia (I) was calculated at the fracture site as an ellipse, I =
π/64(AB3-ab3) (Bak & Jensen 1992).
4.1.2 Histomorphometric analyses
In Study I, the femur was fixed for 24 h with 10% formalin (Formal-FixxTM, Thermo
Shandon, UK), decalcified (TBD-2TM, Thermo Shandon, UK), dehydrated in graded ethanols
and acetone and then embedded in paraffin. Three 5-μm-thick paraffin-embedded horizontal
bone sections were cut from the proximal end of the diaphysis and dyed with a haematoxylin-
eosin stain. Bone diameter, inner bone diameter and cortical width of the sections were
measured using a 2x objective and a Nikon micrometer on a Nikon Eclipse E400 microscope.
In addition to these measurements, the section modulus was calculated.
In Study II, bone labelling with an intraperitoneal injection of tetracycline (15 mg/kg,
Oxytetracyclin, Pfizer) was performed 12 and 2 days prior to sacrifice.
For tissue collection, both hind legs were disarticulated at the hip, knee and ankle. The length
of the right femur was measured. The samples were dehydrated in graded concentrations of
ethanol and embedded undecalcified in methylmethacrylate. Longitudinal frontal sections of
the distal femur were cut at a thickness of 7 µm using a Polycut S heavy-duty microtome
(Leica Instruments GmbH, Heidelberg, Germany). The mineral apposition rate (MAR,
µm/day) was measured in these sections by double tetracycline labelling using an MCID/M4
image analyser (Imaging Research Inc., Canada) and a Sony DXC 930P camera (Japan). The
sections were stained with the Masson-Goldner-Trichrome method for studying structural
properties. Histomorphometry was performed with a semiautomatic image analysing system
linked to a light microscope (Nikon Optihot II, Japan). Trabecular bone area (Tb.Ar, %), total
trabecular perimeter (B.Pm, mm), trabecular width (Tb.Wi, µm) and osteoblast perimeter
(Ob.Pm, mm) were measured, and osteoclast number (Oc.N) was calculated.
4.1.3 Assessment of blood chemistry
At the end of the study, blood samples were drawn by cardiac puncture for serum parathyroid
hormone (s-PTH) assessment with a Rat-intact PTH ELISA Kit (Immutopics, Inc., San
Clementine, CA, USA). In Study II, serum calcium and phosphate concentrations were
assessed with an automatic analyser (Konelab 20, Thermo Clinical Labsystems Oy, Espoo,
Finland).
4.2 Experimental design for in vitro experiments (Studies III and IV)
4.2.1 Cell cultures
UMR-106 rat osteosarcoma cells (American Type Culture Collection) were grown in
Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% FCS, 50 IU
penicillin and 50 ?g/ml streptomycin at 37°C in a humified atmosphere with 5% CO2 on 96–
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well plates. The cells were seeded at 1 x 104 cells/cm², cultured for 24 h, and the medium was
then changed to a fresh medium containing various concentrations of IPP, VPP or LKP.
Human mesenchymal stem cells (hMSC, Poietics, Cambrex Bio Science, Walkerville,
Maryland, USA) purified from human bone marrow were seeded at 3100 cells/cm² and
cultured in Poietics mesenchymal stem cell growth  medium with mesenchymal cell growth
supplements (Cambrex Bio Science) at 37°C in a humified atmosphere with 5% CO2. At 50%
confluence the medium was substituted either by a fresh growth medium (?-MEM, 10% FBS,
100 U/ml penicillin, and 100 U/ml streptomycin) or differentiation medium (?-MEM, 10%
FBS, 10-8 M Dex, 50 ?g/ml L-ascorbic acid, and 10 mM ?–GP, 100 U/ml penicillin, 100 U/ml
streptomycin). After 12-14 days of differentiation the osteoblastic phenotype was confirmed
by amplifying osteocalcin with qRT-PCR, by alkaline phosphatase staining (Sigma
histological alkaline phosphatase kit no. 86) and by assessing mineralization with Alizarin
Red S staining (Bodine et al. 1996).
4.2.2 Tripeptides IPP, VPP and LKP
Peptides were synthesized in the Core Facility for Synthetic Peptides (Division of
Biochemistry, Department of Biological and Environmental Sciences), University of Helsinki,
Finland) by 9-fluorenylmethyloxycarbonyl (Fmoc) chemistry and purified by HPLC reverse-
phase columns.
4.2.3 Analytical methods for in vitro experiments
4.2.3.1 Microarray analysis
Total RNA from the hMSC differentiated osteoblasts, and IPP-treated osteoblasts was
extracted using a RNeasy Protect mini-kit (Qiagen GmgH, Hilden, Germany). The RNA
concentration was measured at 260 nm by a spectrophotometer (SmartSpec
TM
3000 Biorad).
The cDNA microarray hybridizations were performed at the Finnish DNA Microarray Centre,
University of Turku. The expression profiles of osteoblasts differentiated from hMSC were
compared after a 24-h treatment with 50 ?M IPP, VPP or LKP with a Hum16-K protocol,
consisting of 16 000 human gene probes. Microarray data were processed with ScanArray and
QuantArray. LOWESS normalizations, t-test and gene-expression profiles were analysed by
Kensington Discovery Edition 2.0 software and TIGR Multi Experiment Viewer (MeV). A p-
value of  0.05 was used as a limit for statistically significant differences in expression. Data
were then further filtered according to fold difference in expression. At least a 1.8 fold
difference was used in control/treatment comparison.
4.2.3.2 Quantitative RT-PCR
Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was performed in a
real-time quantitative PCR (Mx3000P, Stratagene) according to the manufacturer’s
instructions using a Brilliant SYBRGreen QPCR Master mix kit (Stratagene) and cDNAs as
templates. Fluorescence data were collected during the annealing step and analysed with
Mx3000P software. A dilution series of cDNA from human brain total RNA (BD,
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Biosciences, Clontech) was used as a calibration standard, and the data were normalized by
amplification result of ß-actin. All reactions were run in triplicate.
In study III, we used the same cDNA as in the microarray analysis (control and 50 µM, 24-h
IPP-treated). The mean value was used to calculate the ratio of target gene/?-actin expression
in each sample. Using the ratio in the untreated sample as a standard (100), the relative ratio
of the treated sample was presented as the relative expression level of the target gene.
In study IV, the qPCR analysis was carried out on days 13, 17 and 20 of culture on hMSC-
differentiated osteoblasts and osteoblasts treated with 50 µM IPP; hence, the results represent
later stages of osteoblast differentiation. All qPCR primers are shown in Table 1.
Table 1: Nucleotide sequences of primers used for quantitative RT-PCR detection.
Gene Primer sequence Product
size (bp)
Reference
?-actin F: AGG CCA ACC GCG AGA AGA TGA CC
R: GAA GTC CAG GGC GAC GTA GCAC
350 Wordinger
et al. 2002
?-catenin F: TTC TGG TGC CAC TAC CAC AGC
R: TGC ATG CCC TCA TCT AAT GTC
216 Wang
et al. 2000
BMP-2 F: GGA GAA GGA GGA GGC AAG
R: GAC ACG TCC ATT GAA AGA GC
100 Emmanuele
et al. 2003
BMP-5 F: AAG AGG ACA AGA AGG ACT AAA AAT AT
R: GTA GAG ATC CAG CAT AAA GAG AGGT
303 Wordinger
et al. 2002
Caspase-8 F: AGG AGG AGA TGG AAA GGG AAC TT
R: ACC TCA ATT CTG ATC TGC TCA CTT CT
108 Gomez
et al. 2003
Cbfa1/Runx2 F: TGA GAG CCG CTT CTC CAA CC
R: GCG GAA GCA TTC TGG AAG GA
266 Primer3
CREB-5 F: GCT TTG GTG CTT TTC TCC AG
R: GGT GAC ACC ACA GCA CAA AC
245 Primer3
OPG F: GGC AAC ACA GCT CAC AAG AA
R: CTG GGT TTG CAT GCC TTT AT
241 Kusumi
et al. 2005
OCN F: ATG AGA GCC CTC ACA CTC CTCG
R: GTC AGC CAA CTC GTC ACA GTCC
255 Kuliwaba
et al. 2000
Osteoglycin F: TTG ATG CTG TAC CAC CCT TAC
R: ATT CCA GGG CAT TAT GGT CC
348 Primer3
RANKL F: AGA GCG CAG ATG GAT CCT AA
R: TTC CTT TTG CAC AGC TCC TT
180 Primer3
PTHrP F: GTC TCA GCC GCC GCC TCA A
R: GGA AGA ATC GTC GCC GTA AA
93 Richard
et al. 2003
VDR F: CCA GTT CGT GTG AAT GAT GG
R: CCT TTT GGA TGC TGT AAC TG
256 Primer3
All primer sequences used were designed as described previously, except primer pairs for
Cbfa1/Runx2, CREB-5, osteoglycin, RANKL and VDR, which were designed with Primer 3
–software for this study.
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4.2.3.3 Assessment of cell proliferation
The proliferation experiment was carried out with 5, 50 and 500 ?M peptide concentrations
and 6-, 24- or 48-h treatment time. DNA synthesis activity was assessed by a Cell
Proliferation ELISA kit (Roche Diagnostics GmbH, Germany). The 5-bromo-2’-deoxyuridine
(BrdU) incorporation was measured with a spectroscopic plate reader at 450 nm (Multiskan
Ex, Thermo Labsystems, Helsinki, Finland).
4.2.3.4 Assessment of total protein content
Total protein content was assessed from cells grown on the 24-well plates according to the
Bradford method (Bradford 1976) on days 3, 7, 12, 14, 17, 21 and 34 of culture. Bovine
serum albumin (Sigma) was used as a standard.
4.2.3.5 Assessment of bone alkaline phosphatase activity
Bone-specific alkaline phosphatase (bALP) activity was measured at seven time-points with
an OCTEIATM Ostase® BAP immunoenzymetric assay (Immunodiagnostic Systems Limited,
Boldon, UK) from cells grown on the 24-well plates. Prior to measurement, cells were
washed with phosphate-buffered saline (PBS) and frozen (-70?C) with 300 ?l of Tris –Triton
(0.1 M Tris –base, 0.2% Triton X-1000). After thawing, the cells were centrifuged (12000 g,
5 min). Supernatant was used for the analysis. The ALP activity was corrected with the
protein content according to the Bradford method (Bradford 1976).
4.2.3.6 Assessment of mineralization
Cell culture mineralization was assessed by Alizarin Red S staining from cells grown on the
96-well plates (Bodine et al. 1996). After staining, the dye was eluated with a solution of 10%
cetylpyridinium chloride and 10 mM sodium phosphate (pH 7.0, 15 min, RT). Absorbance
was measured at 590 nm (Multiskan Ex, Thermo Labsystems, Helsinki, Finland).
4.3 Statistical analyses
In Study I, comparisons between groups for BMD were tested by analysis of covariance
(ANCOVA) with baseline bone mineral values and changes in body weight were used as
covariates. Paired samples t-test was used to analyse changes within a group over the study
period. Independent samples t-test was used to compare s-PTH concentration between groups.
The correlation coefficient was tested by Pearson’s correlation. Results were considered
significant at a 95% significance level (p<0.05). Analyses were carried out using SPSS for
Windows (version 12.0).
In Study II, we used one-way ANOVA, followed by Tukey’s post-hoc test to determine the
effects of diets or the least-significant difference (LSD) post-hoc test for pQCT values. For
nonparametric values, the Kruskall-Wallis post-hoc test was used. Correlations between
measured variables were tested for the whole group by Pearson’s correlation, except for
micro-CT, where Spearman’s rho was used. Principal component analysis (PCA) was used to
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analyse the histomorphometric measures and to determine the main components affected by a
high-phosphate diet. Results were considered significant at 95% significance level (p < 0.05).
The analyses were performed using SPSS for Windows (version 12.0).
In Studies III and IV, statistical analyses were performed with GraphPad Prism software
(version 3.03) and SPSS for Windows (version 12.0). Data were analysed using either
Student’s unpaired t-test or ANOVA, followed by Tukey’s post-hoc test. The microarray gene
expression data for IPP-treated osteoblasts were analysed by PCA to categorize the affected
genes. Results were considered significant at the 95% significance level (p<0.05).
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5 RESULTS
5.1 In vivo Studies I and II
5.1.1 High phosphate intake reduced bone growth and mineral accrual (Study I and II)
In Study I, femur bone mineral density increased significantly in the control group, but not in
the phosphate group when initial BMD and weight gain were used as covariates (Figure 8A).
Lumbar (L4-6) BMD decreased in both groups  (phosphate group -0.0026 ± 0.024 g/cm² and
controls -0.0059 ± 0.024 g/cm²). The decrease in lumbar BMD was less in the phosphate
group (Figure 8B).
In Study II, the Ca:P 1:3 rats had significantly shorter femurs than control or Ca:P 1:2 rats
(p=0.001 and p=0.019, respectively). According to DXA results, final femur area values were
not affected by a high phosphate intake. Both of the high-phosphate groups had significantly
lower BMC and areal BMD than control rats (p<0.001 and p<0.001, respectively) (Figure
BMD C). When the final DXA results were adjusted by femur length, the results remained
unchanged. However, the DXA results must be interpreted with caution because rat body
sizes differed between the groups. Weight-independent results from pQCT and micro-CT
measurement are more reliable.
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Figure 8: A) In aged rats (n = 20) femur ?BMD was greater in control rats than in phosphate
rats (p = 0.005). B) Spine BMD was reduced over the study period in aged rats. The reduction
was greater in control rats (p = 0.007). C) In growing rats (n = 30) femur ?BMD was reduced
by high phosphate diet, (p < 0.001). Results are mean ± SD.
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5.1.2 Tibia mineral content was unaffected by high phosphate diet (Study I)
No significant difference was found between groups in tibia calcium and phosphate content.
Tibia BMC/body weight correlated with section modulus (r=0.560, p=0.016) as well as with
calcium and phosphate content/bone length (r=0.979, p<0.001 and r=0.974, p<0.001,
respectively).
5.1.3 High phosphate intake attenuates cortical bone (Study II)
The femur pQCT measurement showed high phosphate diet to affect cortical bone more
severily than trabecular bone. In the distal metaphysis a high-phosphate diet decreased
cortical cross-sectional area (CSA). Cortical BMC was decreased dose-dependently. The
endoperi–ratio, representing trabecular CSA/cortical CSA, was increased with the Ca:P 1:2
diet as compared with the other diets. This was a result of increased trabecular CSA in Ca:P
1:2 rats. However, total bone CSA (TB CSA) was reduced as was the total bone BMC (TB
BMC).
In the femur midshaft, TB BMC and TB CSA decreased with increasing phosphate intake.
Phosphate-rich diets did not affect trabecular bone, but decreased cortical BMC, CSA and
thickness dose-dependently.
Our interpretation of the results is that periosteal and longitudinal growth were lower and
endocortical resorption higher in the high-phosphate diet, leading to an absolute thinner
cortex. Thus, the phosphate-rich diet restricted growth, resulting in short bones with a thin
cortex and a lower absolute amount of bone. The volumetric total bone BMD (TB BMD) was
reduced with a high-phosphate diet (control vs. Ca:P 1:3), hence there is less accrual in
smaller bones. The volumetric TB BMD differs in the femur midshaft, but not in the distal
metaphysis.However, the amount of trabecular bone (Trab CSA/Cort CSA) in the distal
metaphysis differs between groups (p=0.003), whereas in the femur midshaft it does not.
Bone metabolism is accelerated in the high-phosphate group, and this compensates some of
the decrease in mineral accrual, but only in the distal metaphysis, as it has more trabecular
bone. The femur midshaft has less trabecular bone, hence, the accelerated trabecular
metabolism is not sufficient to compensate for the mineral loss in the cortical parts.  Table 2
summarizes the high phosphate effects on bone measurements.
5.1.4 Bone microstructure was decreased due to high phosphate intake (Study II)
Micro-CT analysis showed a high-phosphate intake to decrease bone volume (BV) and bone
surface (BS) values in trabecular bone. Trabecular separation (Tb.Sp) was largest in Ca:P 1:2
rats. The structure model index (SMI) was lower for Ca:P 1:3 rats, than for control or Ca:P
1:2 animals, indicating an increased plate/rod ratio in trabecular bone architecture. A positive
trend was found in the Ca:P 1:3 diet in increasing the number of connective structures per unit
volume (E.Conn.D).
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In cortical bone, the total cross-sectional area (B.Ar) was decreased by a high phosphate
intake. Cortical porosity (Po) had increased trend in high phosphate groups and a positive
correlation with s-PTH. Cortical porosity and tibia ultimate strength had a negative
correlation.
Table 2: Summary of the high dietary phosphate effect on bone measurements after 8 week
feeding (? increase, ? decrease, ? no difference).
                                                             Study I,
                                                            adult rats
Study II,
growing rats
Ca:P 1:2 Ca:P 1:2 Ca:P 1:3
Femur DXA
BMD (g/ cm²) ? ?
BMC (g) ? ? ?
Area (cm²) ? ? ?
Lumbar DXA ?
BMD
BMC ?
Area ?
Tibia Ca and P content ?
Femur length (cm) ? ?
pQCT of distal metaphysis
TB BMD (g/cm3) ? ?
TB BMC (g) ? ?
TB CSA (mm2) ? ?
Trab BMD (g/cm3) ? ?
Tra BMC (g) ? ?
Trab CSA (mm2) ? ?
Cort BMD (g/cm3) ? ?
Cort BMC (g) ? ?
Cort CSA (mm2) ? ?
Mean Cort Th (mm) ? ?
Endoperi ratio ? ?
pQCT of femur midshaft
TB BMD (g/cm3) ? ?
TB BMC (g) ? ?
TB CSA (mm2) ? ?
Trab BMD (g/cm3) ? ?
Tra BMC (g) ? ?
Trab CSA (mm2) ? ?
Cort BMD (g/cm3) ? ?
Cort BMC (g) ? ?
Cort CSA (mm2) ? ?
Mean Cort Th (mm) ? ?
Endoperi ratio ? ?
Section modulus ? ?
(continues)
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(Table 2 continues)
Ca:P 1:2 Ca:P 1:3
Tibia micro-CT
End.Pm/Peri.Pm ? ?
MMI(polar) (mm4) ? ?
Trabecular bone
TV (mm³) ? ?
BV (mm³) ? ?
BS (mm²) ? ?
Tb.Th (mm) ? ?
Tb.Sp (mm) ? ?
Tb.N (mm-¹) ? ?
SMI ? ?
E.Conn.D (mm-³) ? ?
DA ? ?
Cortical bone
B.Ar (mm²) ? ?
Ct.Th (mm) ? ?
Po (%) ? ?
Mechanical competence of the femoral neck
Ultimate strength (N) ? ?
Stiffness (N/mm) ? ?
Toughness (Nm x 10 -3) ? ?
Yield point ? ?
Mechanical competence of tibia shaft
Ultimate strength (N) ? ?
Stiffness (N/mm) ? ?
Toughness (Nm x 10-3) ? ?
Yield point ? ?
5.1.5 High phosphate intake reduced bone mechanical competence (Study II)
Dietary phosphate reduced femur shaft ultimate strength and yielding point dose-dependently.
Ca:P 1:2 rats had 10% lower values for femur ultimate strength and 20% lower values for
shaft yielding point than controls. The respective values for Ca:P 1:3 rats were 24% and 36%
lower. PTH values had a negative correlation with femur ultimate strength, yielding point and
toughness.
High phosphate intake reduced tibia mechanical competence. Values for Ca:P 1:2 tibias were
12% lower in ultimate strength, 11% lower in stiffness and 32% lower in toughness than for
control tibias. In Ca:P 1:3 tibias, the corresponding values were 29%, 24% and 40%. Serum
PTH correlated negatively with all of the above values.
In addition to decreased mechanical competence, tibia material properties were decreased.
The stress-strain relationship is presented in Figure 9A. Stress values for yield, maximum
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stress and fracture revealed that a high-phosphate diet reduces yield and maximum stress
(Figure 9B).
Figure 9: The stress-strain curve (A) and maximum stress values (B) for tibiae (n = 30). The
high-phosphate diet reduced stress endurance, leading to lower yield and lower maximum
stress values (* p<0.05, ** p<0.01). Results are mean ± SE.
5.1.6 Bone metabolim was increased by high phosphate intake (Study I and II)
In Study I, no significant differences emerged between groups in any of the measured
morphometric parameters of the femur midshaft. Femur ?area and spine ?area had a negative
correlation, and femur ?area and femur cortex width had a positive correlation. Section
modulus and periosteal and endosteal radius correlated with the following variables only
within control animals: final femur area, femur ?area and cortex. Values correlating
negatively within the phosphate group only were lumbar spine ?area with both femur
diameter and marrow diameter.
In Study II, high phosphate intake reduced Tb.Ar and Tb.Wi dose-dependently and B.Pm, but
increased Ob.Pm, Oc.N and MAR. S-PTH had a positive correlation with Oc.N and MAR,
whereas final femur BMD had a negative correlation with Oc.N and MAR.
According to PCA, 71% of the variance in the six histomorphometric variables could be
attributed to the first principal component. Because it had heavy positive loadings (>0.8) on
Tb.Ar, Tb.Wi, and B.Pm. and heavy negative loadings (<-0.6) on Ob.Pm, Oc.N, and MAR, it
was named ‘Bone volume’. The bone volume was highest in the control group, whereas high
dietary phosphate intake resulted in lower bone volume.
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5.1.7 High phosphate intake increased serum PTH (Studies I and II)
Serum PTH was significantly higher in the phosphate group at the end of the Study I (Figure
10A). In Study II, serum PTH was significantly higher in Ca:P 1:3 rats  than in control or
Ca:P 1:2 rats (Figure 10B). Serum calcium and phosphate did not differ between groups.
Serum calcium had a positive correlation with final femur BMD. Serum phosphate had a
positive correlation with s-PTH.
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Figure 10: High-phosphate diet elevated serum PTH in the adult rats (n = 20) (A) and growing
rats (n = 30) (B). *p < 0.05, ***p < 0.001. Results are mean ± SD.
5.1.8 Body weight gain and food intake (Studies I and II)
In Study I, the initial body weight, weight gain and final body weight did not differ between
groups (Figure 11A). Body weight of rats in both groups significantly increased over the 8–
week study period. Food intake was not recorded.
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Figure 11: Weight evolution in aged rats (n 0 20) (A) and growing rats (n = 30) (B). Weight
gain was significantly less in growing rats fed high phosphate diet (p < 0.001). Results are
mean ± SD.
In Study II, a high-phosphate diet reduced growth. Rats in the Ca:P 1:2 group were 11%
lighter and rats in the Ca:P 1:3 group 29% lighter than controls (Figure 11B). Due to lower
body weight, the total food consumption was also less in high-phosphate groups (control, 10.3
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kg; Ca:P 1:2, 9.9 kg; Ca:P 1:3, 9.2 kg). Adjusted food consumption (g of food/g of weight
gain) varied between groups. In order to gain 1 g of weight, a rat needed to consume 2.5 g of
control diet, 2.6 g of  Ca:P 1:2 diet or 3.2 g of  Ca:P 1:3 diet. The relative food consumption
was 28% more in the Ca:P 1:3 group than in the control group.
To sum up the results of Studies I and II, an increased intake of dietary phosphate hindered
mineral deposition into cortical bone and diminished BMD in aged rats. Phosphate elevated
PTH and conserved trabecular bone, as mineral loss was lower in the lumbar spine with a
phosphate-rich diet. In young rats, increased phosphate intake reduced bone material and
structural properties and led to diminished bone strength. Our study shows a low Ca:P ratio to
exhibit negative effects on mature and growing skeletons even when calcium intake is
sufficient.
5.2 In vitro Studies III and IV
5.2.1 Microarray results from IPP-, VPP- or LKP-treated osteoblasts (Study III)
Microarray data analysis revealed IPP to regulate more genes in osteoblasts than VPP or LKP.
IPP upregulated 270 genes and downregulated 100 genes. The respective numbers for VPP
were 25 and 10 and for LKP 16 and 14. IPP not only regulated a larger number of genes than
VPP or LKP, but IPP was the only tripeptide to upregulate osteogenic differentiation factors
(see Study III, Table 2 for summary).
5.2.2 Quantitative RT-PCR results (Studies III and IV)
In Study III, the qRT-PCR results were in accordance with those of microarray analysis and
showed IPP to increase CREB-5, BMP-5 and PTHrP expression, whereas VDR and caspase-8
expression were decreased. However, the effect of IPP on BMP-2 was not statistically
significant in qRT-PCR analysis (see Study III, Figure 3).
In Study IV, the long-term effects of IPP on osteoblast gene expression are summarized in
Table 3. More detailed figures are found in Study IV, Figure 3.
In short, long-term treatment with IPP increased osteoblast osteoglycin expression and
reduced PTHrP and OPG expression on day 13. On day 17, IPP increased osteoblast ?-catenin
and osteoglycin expression, and reduced Cbfa1/Runx2, CREB-5 and Caspase-8 expression
and RANKL/OPG ratio. On day 20, IPP reduced osteoblast PTHrP expression. Control cell
PTHrP expression was highest on day 13, reduced on day 17 and elevated again on day 20.
IPP inhibited the rise on day 13 and on day 20. Control cell osteoglycin expression did not
differ between days 13, 17, and 20. IPP increased osteoglycin expression on day 13 and day
17. Caspase-8 was elevated in control cells from day 13 to day 17 and reduced from day 17 to
day 20. IPP suppressed the day 17 elevation in caspase-8 expression.
OPG expression did not differ in control cells at day 13, 17, or 20. IPP reduced OPG
expression at day 13. No significant changes occurred in RANKL expression over the study
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period in control or IPP treated cells. RANKL was present in very low concentrations, and
despite four separate RT-PCR analyses the large standard deviation masked potential
difference. The RANKL/OPG ratio was increased in control cells from day 13 onwards. IPP
reduced the RANKL/OPG ratio at day 17.
Table 3: Summary of the RT-qPCR results from long-term treatment with IPP (50 ?M).
IPP 50 ?M
Day 13 Day 17 Day 20
?-catenin ?
Cbfa1/Runx2 ?
PTHrP ? ?
CREB-5 ?
Osteoglycin ? ?
Osteocalcin
Caspase-8 ?
OPG ?
RANKL
RANKL/OPG ?
5.2.3 Cell proliferation (Study III)
IPP, VPP and LKP increased UMR-106 cell proliferation as compared with that of control
cells. A 24-h treatment with 50 ?M IPP increased hMSC cell proliferation. In a dose-response
study with mature osteoblasts IPP decreased the proliferation at a concentration of 500 ?M.
There was no time-response on osteoblast proliferation with 50 ?M IPP at 3, 24 or 48 h
(Figure 12).
5.2.4 Total protein content (Study IV)
Total protein content increased in all groups from day 3  to day 34  (Figure 13A ). Total
protein content did not differ between groups.
5.2.5 Alkaline phosphatase activity (Study IV)
Bone alkaline phosphatase (bALP) activity increased from day 7 onwards in control and IPP-
treated cells grown in an osteoblast differentiation medium, but not in cells grown in
amesenchymal cell growth medium (Figure 13B). bALP activity further increased up to day
21 and remained high until day 34. bALP activity did not differ between IPP-treated
osteoblasts and control cells.
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Figure 12: The effect of IPP tripeptide on cell proliferation in hMSC (A and B) and
differentiated osteoblasts (OB) (C and D). Dose- and time-response. The results are shown as
the relative amounts of BrdU incorporation. The mean amount of BrdU incorporation in the
24 h control cells has been given the value 100 (** p<0.01, *** p<0.001). Results are mean ±
SD (n = 5).
Figure 13: Protein content did not differ between cell cultures (A). bALP activity was
increased in cells grown with osteoblast differentiation medium (B). IPP had no effect on
bALP activity. Results are mean ± SD (n = 3).
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5.2.6 Mineralization (Study IV)
IPP (50 ?M) treatment increased osteoblast mineralization (Figure 14).
Osteoblast mineralization
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To sum up findings of Studies III and IV, short-term treatment with tripeptide IPP, VPP or
LKP had an effect on osteoblast gene expression. IPP in particular, was efficient in regulating
genes associated with cell differentiation, cell growth and cell signal transcription. The
upregulation of these genes indicated that IPP enhances osteoblast proliferation and
differentiation. IPP was confirmed to increase UMR-106 and hMSC proliferation, but not the
proliferation of mature osteoblasts. Long-term treatment with tripeptide IPP enhanced
osteoblast gene expression in favour of bone formation and increased mineralization. Long-
term treatment with IPP did not influence osteoblast differentiation in vitro. However, the in
vivo effects might differ, since eating frequency drives food consumption, and protein
degradation products, such as bioactive peptides, are available periodically, not continuously
as in this study.
Figure 14:
Continuous exposure to 50 ?M IPP increased
osteoblast mineralization (n = 6). Results are
mean ± SD. *p < 0.05
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6 DISCUSSION
Bone health is influenced by diet. Nutrients important for bone growth should therefore be
recommended, but bone-impairing nutrients must also be noted (Ward et al. 2003). In the
daily diet, nutrients are consumed in conjunction foods, and associations attributed to a single
nutrient may in fact be caused by the simultaneous consumption of other nutrients (Tucker et
al. 2002). To study the effect of a single nutrient on bone, structured trials are needed.  This
thesis examines the in vivo effects of inorganic phosphate and the in vitro effects of bioactive
tripeptides on bone. Studies I and II are based on a rodent model and Studies III and IV on
cell culture models.
Studies I and II revealed high intake of inorganic phosphate to have deleterious effects on
bone. High phosphate diet restiricted mineral deposition into cortical bone and resulted to
lower bone mineral accrual in femurs in mature rats (Study I). In order to maintain strength
bones compensated the lack of mineral by an increase in size. Bone loss is part of normal
aging. The rate of bone loss is greater in trabecular than in cortical bone (O’Flaherty 2000).
Vertebrae is mainly composed of trabecular bone (Riggs et al. 1981). All aged rats had a
reduction in lumbar mineral content over the 8-week study, but the decrease was less in the
high phosphate group. Similar difference between cortical and trabecular bone loss was also
seen in growing rats (Study II). The pQCT results revealed high phosphate diet to reduce
cortical thickness and mineral content dose-dependently, whereas trabecular bone was less
affected. Total bone mineral density was reduced only at areas rich in cortical bone but
elsewhere trabecular bone subsidised for mineral loss. In the growing rats high phosphate diet
did not only reduce mineral accrual into cortical bone but also hindered the growth of the
animals. The growth retard was a result of the diet. Something about the high phosphate diet
restrained the animals from growing, in order to gain 1 g of weight an animal had to eat 28%
more of the high phosphate diet than control diet. Smaller rats in the high-phosphate groups
accordingly had smaller bones. Although the total bone length was reduced by high phosphate
diet, the relative width of the long bones was actually increased, as no differences were
present between control and high-phosphate groups in DXA-measured femur areas, pQCT-
measured femur diameter trabecular bone cross-sectional area, or micrometer-measured tibia
fracture-site diameters between groups. Hence, we conclude that high-phosphate diet reduced
cortical mineral content and affected bone geometry.
Further histological investigation of the bones from the Study II revealed high phosphate diet
to increase bone remodelling as the number of bone-resorbing osteoclasts and bone-forming
osteoblasts was increased. Bone remodelling at a normal rate is a necessity for the
maintenance of bone but remodelling beyond appropriate levels results in diminished
structure. The structural deterioration of the tibias was seen in micro-CT results as high
phosphate diet decreased trabecular bone volume and surface, increased trabecular separation
and reduced cortical bone cross-sectional area. The structural and material changes caused by
the high-phosphate diet weakened total bone strength and reduced the stress-strain endurance
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leading to lower ultimate bone strength. Alterations in bone geometry could not overcome
these obstacles.
Many of the deleterious effects of high-phosphate diet, such as the site-dependent action on
cortical and trabecular bone, could be mediated by PTH (Freesmeyer et al. 2001). Serum
concentrations of PTH rise with age in rats and humans (Fox & Mathew 1991, Halloran et al.
2002). Also high dietary phosphorus intake increases s-PTH (Almaden et al, 1996, Almaden
et al. 1998, Kärkkäinen & Lamberg-Allardt 1996, Miyamoto et al. 1998, Koshihara 2001).
Continuously elevated PTH has catabolic effects on bone as it decreases bone mass by
stimulating bone resorption (Ma et al. 2001, Halloran et al. 2002). In addition to reduced bone
mineral content elevated serum PTH impairs bone structure by inducing cortical porosity
(Lotinun et al. 2004, Tazawa et al. 2004). These events are brought about by PTH’s effects on
bone cells. PTH directly stimulates osteoclast activity (Dempster et al. 2005) and indirectly,
via osteoblasts, increases osteoclastogenesis (Locklin et al. 2003, Ma et al. 2001). PTH
increases osteoblast RANKL expression and decreases OPG expression (Ma et al. 2001). The
increase in RANKL/OPG ratio leads to osteoclastogenesis and bone loss. In addition, PTH
inhibits osteoblast collagen synthesis and thus bone-formation (Canalis et al. 1989, Canalis et
al. 1990). As bone toughness is determined by collagen (Currey 2003), changes in collagen
alter the mechanical properties of bone and affect bone strength (Burr 2002). In addition to
bone cells, PTH also acts on chondrocytes. PTH delays chondrocyte hypertrophy (Guo et al.
2006), and downregulates their terminal differentiation and collagen expression (Harrington
et al. 2004). In our Study II the elevated PTH could have affected chondrocyte differentiation
and function in the growth plates and hence impaired the growth of the animals. Elevated
PTH impairs bone in many ways and the elevated s-PTH levels, seen in adult and growing
rats, might well have contributed to the diminished bone strength. However, the growing rats
on Ca:P 1:2 diet (Study II) did not have a significant rise in s-PTH compared with controls,
although many of the measured parameters did decline, indicating that high dietary phosphate
has a bone weakening effect beyond PTH.
Bone strength is a combination of several factors; geometric, structural and material
properties (Peng et al. 1994). Because bone is a metabolically active tissue equipped with a
mechanostat (bone mass and strength are regulated to meet mechanical demands, for review,
see Skerry 2006), a decrease in one factor leads to compensation by an other to maintain the
overall bone strength. In our studies the rats in high-phosphate groups had less mineral
deposited into femurs than control rats, and this was compensated by an increase in bone size.
Bone size directly reflects bone strength; bigger bones have higher absolute strength (Orwoll
2003), but small bones can have similar relative strength if the material properties are equal.
Mineral content is the most important material property affecting bone stiffness and ultimate
strength (Seeman 2003). The mechanical properties of bone vary at different structural levels
(Rho et al. 1998) and in trabecular bone, the overall structure is even more important than
mineral content (Currey 2003). Our results show, that a high-phosphate diet reduces bone
mineral accrual into cortical bone and increases bone remodelling beyond appropriate levels,
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resulting in diminished trabecular bone structure. In the future it would be interesting to
further characterize the effects of high dietary phosphate on osteoblast function in vivo as our
results revealed negative correlation with s-PTH and bone toughness, which could be a result
of decreased collagen in bone matrix. Bone mineral-collagen-ratio could be analysed with a
method such as fourier transform infrared imaging spectroscopy (FT-IRIS).
These studies (I and II) were carried out in rats, as rodent models are commonly used in bone
research. The constraints faced by such a translational study are the continuous longitudinal
growth of bone accompanied by periosteal modelling, the lack of a Haversian system in rats
and the sensitivity of rats to dietary phosphate (Ritskes-Hoitinga et al. 1993, Bagi et al. 1997).
Study II described the effect of  high dietary phosphate on the growing skeleton, hence, the
first two obstacles were overcome, as they are also present in the growing human skeleton.
The lack of a Haversian system in rats can attenuate cortical porosity (Dempster 1993). In
humans, a high-phosphate diet could enhance cortical porosity because of active Haversian
remodelling compared with the rat. To overcome the obstacle of rats being phosphate-
sensitive, we used male rats, which are reported to be more resistant than females to dietary
phosphate (Ritskes-Hoitinga et al. 1993).
Based on these long-term dietary intervention results from animal studies and previous short-
term interventions on humans, it is very likely that a long-term human trial would yield
negative outcome on bones. Short-term high-phosphate and low-calcium interventions on
human subjects have shown elevated s-PTH (Calvo et al. 1990, Brixen et al. 1992,
Kärkkäinen & Lamberg-Allardt 1996), decreased bone formation marker (bALP) (Kärkkäinen
& Lamberg-Allardt 1996) and increased bone resorption markers (S-CTX and U-NTX)
(Kristensen et al. 2005). Besides not being absolutely necessary, a long-term high-phosphate
intervention on humans would be unethical, although it would give the ultimate answer to
speculation about the effect of phosphates on the human skeleton. The results from our
Studies I and II indicate high dietary phosphate to have deleterious effects on rat skeleton,
which could not be overcome by adequate calcium intake. As it is widely accepted that
adequate calcium intake can revert the adverse effects of e.g. high-dietary phosphorus intake
(NIH consensus conference 2001), our results should raise concerns when deciding on
sufficient  calcium and phosphate intake to support bone health.
Our in vitro studies (III and IV) were carried out to investigate the effects of bioactive
tripeptides on human osteoblasts. Bioactive peptides are derived from dietary protein.
Epidemiological data shows dietary protein to have positive effects on bone metabolism (e.g.
Hannan et al. 2000, Hoppe et al. 2000, Kerstetter et al. 2003). We hypothesized that bioactive
peptides would have positive effects on bone as they are produced in hydrolysis of proteins
and have a variety of biological functions in body. We studied the effects of IPP, VPP and
LKP as they are all common food derived peptides, have a structure that is suited for
biological function in addition to tissue building and all possess ACE-inhibitory potential. A
preliminary screening of the tripeptides IPP, VPP and LKP on osteoblast proliferation was
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carried out on UMR-106 cells. The rat osteosarcoma cell-line UMR-106 is commonly used as
a model of the osteoblast phenotype (e.g. Hickman & McElduff 1989, Mitchell et al. 1990).
However, the in vitro studies performed using osteoblasts differentiated from human
mesenchymal stem cells yield more applicable information on human osteoblast function
since the osteosarcoma cell line or mouse osteoblasts might not correctly reflect human
osteoblast function (Shui et al. 2003). Hence, further studies were carried out on hMSC-
differentiated osteoblasts. Study III revealed that all of the tripeptides studied, IPP, VPP and
LKP, increased cell proliferation and induced osteoblast gene-expression. Based on the
proliferation results 50 ?M peptide concentration and 24-h treatment-time were used to
induce hMSCs to differentiate towards osteoblasts before performing microarray analysis.
The results show IPP to be the most effective in regulating osteoblast gene expression in
respect to VPP and LKP. IPP upregulated over 6.5 times more genes and downregulated 4
times more genes than VPP and LKP together. Furthermore, IPP was the only tripeptide to
upregulate osteogenic factors. We therefore further investigated IPP’s short- and long-term
effects on osteoblast differentiation. The short-term effects (Study III) indicated that IPP
increases cell differentiation, growth, transcription and viability. In short-term treatment with
IPP, PTHrP could play a role in mediating these functions, as IPP increased osteoblast PTHrP
mRNA expression. PTHrP produced by osteoblasts is thought to function locally within the
skeletal microenvironment and to propel the bone marrow stromal cells towards the
osteogenic lineage (Karaplis & Goltzman 2000). PTHrP also exerts anti-apoptotic effects
(Karaplis & Goltzman 2000). IPP upregulated PTHrP and the transcription activator CREB-5,
whereas apoptotic caspase-8 was downregulated. These findings indicate that bioactive
peptide IPP can enhance gene expression on mRNA level in a way that increases the
differentiation of hMSC into osteoblast lineage and prolongs cell viability. The osteogenic
action could contribute to increased bone formation.
Long-term treatment with IPP (Study IV) showed enhanced osteoblast gene expression in
favour of bone formation and increased mineralization. Continuous treatment with IPP does
not seem to increase osteoblast differentiation in vitro when assessed by bALP activity. But
since osteoblast differentiation is not regulated by a single set of factors, not all genes need to
be expressed similarily in order to upregulate osteoblast markers (Liu et al. 2003, Osyczka &
Leboy 2005). So eventhough there was no difference between bALP-activity, long-term
treatment with IPP did increase matrix production and mineralization and reduced
RANKL/OPG ratio. All of these factors would contribute to increased bone mass by
enhancing bone-formation and reducing bone-resorption.
The positive osteogenic long-term effects of IPP seem to be mediated by Wnt/?-catenin
pathway rather than PTHrP. Similarily, as PTHrP pushes cells towards the osteogenic lineage
(Karaplis & Goltzman 2000), the Wnt/?-catenin pathway also stimulates osteoblastogenesis
(Gaur et al. 2005). Furthermore, the Wnt/?-catenin pathway activates programs directing cell
proliferation (Kohn & Moon 2005) and cell survival (Kohn & Moon 2005, Krishnan et al.
2006) and represses osteoclastogenesis (Spencer et al. 2006) and adipogenesis (Krishnan et al.
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2006). Ageing is associated with a reciprocal increase in adipogenesis and a decrease in
osteogenesis (Akune et al. 2004). Changing the adipogenic differentiation of MSCs to
osteogenic differentiation will increase bone, as ‘fat’s loss is bone’s gain’  (Pei & Tontonoz
2004). IPPs potential to activate the Wnt/?-catenin pathway further supports our hypothesis of
protein derived bioactive peptides to have positive effects on bone.
To summarize our findings from Studies III and IV, hMSC treatment with IPP favours
osteoblastogenesis in vitro. The short- and long-term treatment mechanisms of action might
vary. Bioactive peptides, such as IPP, may be one of the factors contributing to the positive
skeletal effects that dietary protein has. In vivo IPP might have an even more marked effect.
Peptides are produced from protein rich food at regular and frequent doses which could
enhance their effect. Frequent small meals are known to increase bone quality (Li &
Muhlbauer 1999). Further studies are, however, needed to clarify the in vivo mechanism of
action and effective dose of bioactive tripeptides. It would be valuable also to know the
amount of different active peptides being produced from different sources of protein and their
interactions in vivo.
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7 CONCLUSIONS
Results of our in vivo studies (I and II) indicate that long-term high dietary phosphorus intake
has an unfavourable effect on a rodent bone. In adult male rats, high dietary intake of
inorganic phosphate reduced cortical BMD but protected subjects from trabecular bone loss.
This site-dependent effect could, at least in part, be due to the increase in s-PTH. High-
phosphate rats seemed to compensate for the lack of mineral deposition in femurs by an
increase in cross-sectional size, as the phosphate-rich diet increased periosteal bone formation
and resulted in wider bones. In growing male rats, high phosphate intake impaired animal
growth, limited bone longitudinal growth and restricted femur BMC and BMD build-up. Bone
structure was impaired, as reflected by decreased trabecular area and width and reduced mean
cortical thickness. The changes in material and structural parameters resulted in diminished
bone strength.  Bone histomorphometry revealed increased bone metabolism since osteoclast
number and osteoblast perimeter were increased, leading to an increased mineral apposition
rate. In young rats, triplicating the phosphate intake elevated s-PTH. These results indicate
that a low Ca:P ratio produces negative effects on the rat skeleton even with sufficient
calcium intake.
Our in vitro studies (III and IV) on hMSC established that the bioactive tripeptides IPP, VKP
and LKP increase cell proliferation. IPP, in particular, possesses osteogenic potential, as it
upregulates genes associated with osteoblast differentiation, cell growth and cell transcription
while apoptosis-related genes are downregulated. Short-term IPP treatment favours
osteogenesis by propelling cells towards the osteogenic lineage. IPP’s long-term effects on
osteoblasts comprise increased matrix production and mineralization and a reduced
RANKL/OPG ratio, which could lead to diminished osteoclastogenesis and resorption, further
enhancing bone formation. Long-term treatment with IPP did not affect osteoblast
differentiation when assessed by bone alkaline phosphatase activity. These results support the
conclusion that bioactive peptides, such as IPP, have osteogenic potential and enhance
osteoblast function in vitro.
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